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A B S T R A C T
Background
Osteoarthritis is themost common formof joint disease and the leading cause of pain andphysical disability in the elderly. Transcutaneous
electrical nerve stimulation (TENS), interferential current stimulation and pulsed electrostimulation are used widely to control both
acute and chronic pain arising from several conditions, but some policy makers regard efficacy evidence as insufficient.
Objectives
To compare transcutaneous electrostimulation with sham or no specific intervention in terms of effects on pain and withdrawals due
to adverse events in patients with knee osteoarthritis.
Search strategy
We updated the search in CENTRAL, MEDLINE, EMBASE, CINAHL and PEDro up to 5 August 2008, checked conference
proceedings and reference lists, and contacted authors.
Selection criteria
Randomised or quasi-randomised controlled trials that compared transcutaneously applied electrostimulation with a sham intervention
or no intervention in patients with osteoarthritis of the knee.
Data collection and analysis
We extracted data using standardised forms and contacted investigators to obtain missing outcome information. Main outcomes were
pain and withdrawals or dropouts due to adverse events. We calculated standardised mean differences (SMDs) for pain and relative
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risks for safety outcomes and used inverse-variance random-effects meta-analysis. The analysis of pain was based on predicted estimates
from meta-regression using the standard error as explanatory variable.
Main results
In this update we identified 14 additional trials resulting in the inclusion of 18 small trials in 813 patients. Eleven trials used TENS,
four interferential current stimulation, one both TENS and interferential current stimulation, and two pulsed electrostimulation. The
methodological quality and the quality of reporting was poor and a high degree of heterogeneity among the trials (I2 = 80%) was
revealed. The funnel plot for pain was asymmetrical (P < 0.001). The predicted SMD of pain intensity in trials as large as the largest
trial was -0.07 (95% CI -0.46 to 0.32), corresponding to a difference in pain scores between electrostimulation and control of 0.2 cm
on a 10 cm visual analogue scale. There was little evidence that SMDs differed on the type of electrostimulation (P = 0.94). The relative
risk of being withdrawn or dropping out due to adverse events was 0.97 (95% CI 0.2 to 6.0).
Authors’ conclusions
In this update, we could not confirm that transcutaneous electrostimulation is effective for pain relief. The current systematic review
is inconclusive, hampered by the inclusion of only small trials of questionable quality. Appropriately designed trials of adequate power
are warranted.
P L A I N L A N G U A G E S U M M A R Y
Transcutaneous electrostimulation for osteoarthritis of the knee
This summary of a Cochrane review presents what we know from research about the effect of transcutaneous electrostimulation on
osteoarthritis of the knee.
The review shows that in people with osteoarthritis:
- We are uncertain whether transcutaneous electrostimulation affects pain or your ability to use your knee because of the very low
quality of the evidence.
- Transcutaneous electrostimulation may not have any side effects. We often do not have precise information about side effects and
complications. This is particularly true for rare but serious side effects.
What is osteoarthritis and what is transcutaneous electrostimulation?
Osteoarthritis (OA) is a disease of the joints, such as your knee. When the joint loses cartilage, the bone grows to try and repair the
damage. Instead of making things better, however, the bone grows abnormally and makes things worse. For example, the bone can
become misshapen and make the joint painful and unstable. This can affect your physical function or ability to use your knee.
Transcutaneous electrostimulation, such as TENS, is a kind of pain relief typically using electrical currents applied to the skin.
Transcutaneous electrostimulation machines are typically small, battery-operated machines with 2 electrodes attached. Electrodes are
wires that send the electrical current. Usually, you connect two electrodes from the machine to your skin on the painful area. Your
doctor or physiotherapist will show you how to use it, and most machines can be used at home.
Best estimate of what happens to people with osteoarthritis who use transcutaneous electrostimulation up to 4 weeks after
using it:
Pain
- People who used electrostimulation had an improvement in their pain of about 2 on a scale from 0 (no pain) to 10 (extreme pain) 4
weeks after using it.
- People who used a fake electrostimulation machine or just took their usual treatments had an improvement in their pain of about 2
on a scale from 0 (no pain) to 10 (extreme pain) 4 weeks after using it.
- People had no more average improvement when using electrostimulation, and no more people responded to treatment with electros-
timulation compared with people who used a fake electrostimulation machine or just took their usual treatments (difference of 0%).
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Physical Function
- People who used electrostimulation had an improvement in their physical function of about 2 on a scale from 0 (no disability) to 10
(extreme disability) 4 weeks after using it.
- People who used a fake electrostimulation machine or just took their usual treatments had an improvement in their physical function
of about 1 on a scale from 0 (no disability) to 10 (extreme disability) 4 weeks after using it.
- People using electrostimulation had 1 unit more improvement in their knee function when compared to people who used a fake
electrostimulation machine or just took their usual treatments.
Another way of saying this is:
- 29 people out of 100 who used electrostimulation respond to treatment (29%).
- 26 people out of 100 who used a fake electrostimulation machine or just took their usual treatments respond to treatment (26%).
- 3 more people respond to treatment with electrostimulation compared with people who used a fake electrostimulation machine or
just took their usual treatments (difference of 3%).
Dropouts or withdrawals from the trial because of side effects
- 2 people out of 100 who used electrostimulation dropped out or withdrew from the trial because of side effects (2%).
- 2 people out of 100 who used a fake electrostimulation machine or just took their usual treatments dropped out of the trial because
of side effects (2%).
- There was no difference in the number of people who dropped out of the trial because of side effects (difference of 0%). This could
be the result of chance.
Side effects
- 15 people out of 100 who used electrostimulation experienced side effects (15%).
- 15 people out of 100 who used a fake electrostimulation machine or just took their usual treatments experienced side effects (15%).
- There was no difference in the number of people who experience side effects (difference of 0%). This could be the result of chance.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [ Explanation]
Any type of transcutaneous electrostimulation compared with sham or no intervention for osteoarthritis of the knee
Patient or population: patients with osteoarthritis
Settings: physical therapy practice of outpatient clinic
Intervention: any type of transcutaneous applied electrostimulation
Comparison: sham or no specific intervention
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk* Corresponding risk
Sham or no specific inter-
vention
Any type of transcuta-
neous electrostimulation
Pain
Various pain scales
Median follow-up: 4 weeks
-1.8 cm change on 10 cm
VAS1
29% improvement
-2.0 cm change
(1 -0.2 cm, -1.2 to 0.8
cm)2
33% improvement
(1+4%, -13% to +20%)3
SMD -0.07 (-0.46 to 0.32) 726
(16 studies)
+OOO
very low4
Little evidence of beneficial
effect (NNT: not statistically
significant)
The estimated pain in the in-
tervention group of large tri-
als was derived from meta-
regression using the stan-
dard error as independent
variable
Function
Various validated function
scales
Median follow-up: 4 weeks
-1.2 units on WOMAC
(range 0 to 10)1
21% improvement
-2.3 units on WOMAC
(1 -1.1, -1.6 to -0.6)5
41% improvement
(1 +20%, +11% to
+29%)6
SMD -0.34
(-0.54 to -0.14)
407
(9 studies)
+OOO
very low7
NNT: 29 (95% CI 19 to 69)8
Number of patients ex-
periencing any adverse
event
Median follow-up: 4 weeks
150 per 1000 patient-
years1
153 per 1000 patient-years
(80 to 296)
RR 1.02 (0.53 to 1.97) 175
(3 studies)
++OO
low9
No evidence of harmful ef-
fect
(NNH: not statistically sig-
nificant)
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Number of patients with-
drawn or dropped out be-
cause of adverse events
Median follow-up: 4 weeks
17 per 1000 patient-years1 16 per 1000 patient-years
(3 to 102)
RR 0.97 (0.16 to 6.00) 363
(8 studies)
+++O
moderate10
No evidence of harmful ef-
fect
(NNH: not statistically sig-
nificant)
Number of patients expe-
riencing any serious ad-
verse event
Median follow -up: 4 weeks
4 per 1000 patient-years1 1 per 1000 patient-years
(0 to 29)
RR 0.33 (0.02 to 7.32) 195
(4 studies)
++OO
low11
No evidence of harmful ef-
fect
(NNH: not statistically sig-
nificant)
*The basis for the assumed risk in the safety outcomes (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based
on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; GRADE: GRADE Working Group grades of evidence (see explanations); NNT: number needed to treat; NNH: number needed to harm; RR: risk ratio; SMD: standardised mean
difference
GRADE Working Group grades of evidence
High quality (++++): Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality (+++O): Further research is likely to have an important impact on our confidence in the estimate of effect and may
change the estimate.
Low quality (++OO): Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely
to change the estimate.
Very low quality (+OOO): We are very uncertain about the estimate.
1 Median reduction as observed across control groups in large osteoarthritis trials (Nuesch 2009).
2 Standardised mean differences (SMDs) were back-transformed onto a 10 cm visual analogue scale (VAS) on the basis of a typical
pooled SD of 2.5 cm in trials that assessed
pain using a VAS, and expressed as change based on an assumed standardised reduction of 0.72 standard deviation units in the control
group.
3 The median observed pain score at baseline across control groups in large osteoarthritis trials was 6.1 cm on a 10 cm VAS (Nuesch
2009).
4 Downgraded (3 levels) because the effect was estimated from a meta-regression model using the standard error as independent variable
and because included trials were generally of low quality and small sample size: only 2 out of 16 trials used adequate concealment of
allocation, only 3 performed analyses according to the intention-to-treat principle, and the presence of large between trial heterogeneity.
5 Standardised mean differences (SMDs) were back-transformed onto a 0 to 10 standardised WOMAC function score on the basis of a
typical pooled SD of 2.1 in trials that
assessed function on WOMAC function scale and expressed as change based on an assumed standardised reduction of 0.58 standard
deviation units in the control group.
6 The median observed standardised WOMAC function score at baseline across control groups in large osteoarthritis trials was 5.6 units
(Nuesch 2009).
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7 Downgraded (3 levels) because included trials were generally of low quality and small sample size: 1 out of 9 studies used adequate
concealment of allocation methods, only 2 performed analyses according to the intention-to-treat principle, presence of moderate
between trial heterogeneity, 9 out of 18 studies reported this outcome, likely leading to selective outcome reporting bias.
8 Absolute response risks for function in the control groups were assumed 26% (see Methods section).
9 Downgraded (2 levels) because the confidence interval crosses no difference in the pooled estimate, 1 out of 3 studies included all
patients in this analysis, 3 out of 18 studies reported this outcome, likely leading to selective outcome reporting bias.
10 Downgraded (1 level) because the confidence interval of the pooled estimate is wide and crossed no difference, 8 out of 18 studies
reported this outcome, possibly leading to selective outcome reporting bias.
11 Downgraded (2 levels) because 4 out of 18 studies reported this outcome, possibly leading to selective outcome reporting bias, the
confidence interval of the pooled estimate is wide and crossed no difference.
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B A C K G R O U N D
Osteoarthritis is an age-related condition, occurring more fre-
quently in women than in men. Its prevalence, causal associations
and outcomes vary markedly according to the joint site affected (
Jüni 2006). Osteoarthritis is characterised by focal areas of loss of
articular cartilage in synovial joints, accompanied by subchondral
bone changes, osteophyte formation at the joint margins, thick-
ening of the joint capsule and mild synovitis (Solomon 1997).
The objectives of management of knee osteoarthritis are to relieve
pain and to maintain or improve function. Different modalities in
physiotherapy have been suggested to improve the clinical course
of knee osteoarthritis, with potentially fewer adverse effects than
medical treatment (Bjordal 2007; Jamtvedt 2008), but some pol-
icymakers consider the evidence for effectiveness to be insufficient
(Gezondheidsraad 1999).
Transcutaneous electrostimulation, the application of any electri-
cal current through the skin with the aim of pain modulation, is
a frequently used modality in knee osteoarthritis (Carroll 2001;
Osiri 2000). It is based on the ’Gate-Control Theory’ of pain per-
ception as described by Melzack and Wall (Melzack 1965). The
theory suggests that the stimulation of large diameter, (A-beta)
primary sensory afferent cutaneous fibres activates inhibitory in-
terneurons in the spinal cord dorsal horn and, thereby, may atten-
uate the transmission of nociceptive signals from small diameter
A-delta and C fibres. Other suggested mechanisms include a stim-
ulation of β endorphin production (Andersson 1976; Grimmer
1992; Mayer 1989) and even the potential for articular cartilage
repair (Fary 2008; Haddad 2007).
Several types of electrostimulation are available. Conventional
transcutaneous electrical nerve stimulation (TENS), in its narrow
sense, uses moderate to high frequency current of 40 to 150 Hz
and 50 to 100 µsec pulse width, typically at a low intensity, to
stimulate sensory fibres. Several other types of TENS were subse-
quently developed, which differ in intensity, pulse width or fre-
quency. Acupuncture-like TENS (ALTENS) uses a low frequency
current of 0.5 to 10 Hz and a pulse width of > 150 µsec at a high
intensity to stimulate both motor and sensory fibres. The stim-
ulation may be painful, and the intensity of the current will de-
pend on the patient’s individual pain tolerance. Burst TENS was
developed to minimise patients’ discomfort, as experienced with
AL TENS. It uses short bursts of high frequency current of typi-
cally 80 to 100 Hz, which are repetitively applied at low intensity
and a burst frequency of around 5 Hz, to stimulate motor and
sensory fibres. The intensity used is slightly higher than used with
conventional TENS. Brief TENS uses a high frequency current
of more than 100 Hz and 150 to 250 µsec pulse width at the
maximal intensity tolerated by the patient to stimulate not only
motor and sensory, but also nociceptor fibres. Modulation TENS
combines several of the modalities above, typically using alterna-
tions of low and high frequency currents (Brosseau 2004; Sluka
2003). Classical interferential current stimulation simultaneously
uses two non-modulated biphasic pulsed currents applied with
two sets of electrodes with four electrical poles; one current is fixed
at approximately 4000 Hz and the other ranging typically from
4000 to 4100 Hz. The superimposition of the two currents results
in a new frequency with a range from 1 to 100 Hz (Wadsworth
1980). Modulated interferential current stimulation uses directed
currents between two electrical poles and vectorially sums currents
in the tissue, with a carrier frequency typically set at 4000 Hz, a
beat frequency at 80 Hz, and a modulation frequency set between
0 to 150 Hz. The effective frequency is defined by the sum of beat
and modulation frequency and varies between 80 and 230 Hz.
The high frequency of the carrier currents in inferential current
stimulation leads to a considerably lower impedance of skin and
subcutaneous tissue as compared with conventional TENS and
minimises patients’ discomfort. Lastly, pulsed electrostimulation
applies high frequency current of 100 Hz and a pulse width of 640
to 1800 µsec, typically using knee garments with flexible, embed-
ded electrodes and a small battery-operated generator, allowing
application times of several hours rather than 15 to 60 minutes,
as is the case for any other of the modalities described above.
O B J E C T I V E S
We set out to compare transcutaneous electrostimulation with
sham or no specific intervention in terms of effects on pain and
function and safety outcomes in patients with knee osteoarthritis
and to explore whether potential variation between trials could
be explained by characteristics of the electrostimulation, by biases
affecting individual trials or by publication bias.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised or quasi-randomised controlled trials with a control
group receiving a sham intervention or no intervention.
Types of participants
Studies including at least 75% of patients with clinically and/or
radiologically confirmed osteoarthritis of the knee.
Types of interventions
Any type of transcutaneous electrostimulation with electrodes set
to stimulate nerves supplying the knee joint area aiming at pain
relief.We did not consider transcutaneous electrostimulation aim-
ing at muscle strength enhancement, such as neuromuscular elec-
trostimulation, and electrostimulation not directly aimed at stim-
ulating nerves of the knee joint area, such as transcranial appli-
cations or transcutaneous spinal electroanalgesia. There were no
restrictions related to the type of electrode used.
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Types of outcome measures
Main outcomes
Main outcomes were pain intensity as the effectiveness outcome (
Altman 1996; Pham 2004) and withdrawals or drop-outs because
of adverse events as the safety outcome. If data on more than
one pain scale were provided for a trial, we referred to a previ-
ously described hierarchy of pain-related outcomes (Jüni 2006;
Reichenbach 2007) and extracted data on the pain scale that is
highest on this hierarchy:
1. Global pain
2. Pain on walking
3. WOMAC osteoarthritis index pain subscore
4. Composite pain scores other than WOMAC
5. Pain on activities other than walking
6. Rest pain or pain during the night
7. WOMAC global algofunctional score
8. Lequesne osteoarthritis index global score
9. Other algofunctional scale
10. Patient’s global assessment
11. Physician’s global assessment
If pain outcomes were reported at several time points, we extracted
the estimate at the end of the treatment period.
Secondary outcomes
Secondary outcomes were function, the number of patients expe-
riencing any adverse event and patients experiencing any serious
adverse events. We defined serious adverse events as events result-
ing in hospitalisation, prolongation of hospitalisation, persistent
or significant disability, congenital abnormality/birth defect of off-
spring, life-threatening events or death.
If data on more than one function scale were provided for a trial,
we extracted data according to the hierarchy presented below.
1. Global disability score
2. Walking disability
3. WOMAC disability subscore
4. Composite disability scores other than WOMAC
5. Disability other than walking
6. WOMAC global scale
7. Lequesne osteoarthritis index global score
8. Other algofunctional scale
9. Patient’s global assessment
10. Physician’s global assessment
If function outcomes were reported at several time points, we
extracted the estimate at the end of the treatment period. For safety
outcomes, we extracted end of trial data.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled
Trials (CENTRAL) (The Cochrane Library 2008, issue 3),
MEDLINE and EMBASE through the Ovid platform (
www.ovid.com), CINAHL through EBSCOhost, Physiotherapy
EvidenceDatabase (PEDro, http:/ / www.pedro.fhs.usyd.edu.au/,
from 1929 onwards), all from implementation to 5 August 2008,
using a combination of keywords and text words related to elec-
trostimulation combined with keywords and text words related to
osteoarthritis and a validated filter for controlled clinical trials (
Dickersin 1994). The search strategy is presented in Appendix 1
and Appendix 2.
Searching other sources
Wemanually searched conference proceedings, used Science Cita-
tion Index to retrieve reports citing relevant articles, contacted con-
tent experts and trialists and screened reference lists of all obtained
articles, including related reviews. Finally, we searched several
clinical trial registries ( www.clinicaltrials.gov, www.controlled-
trials.com, www.actr.org.au, www.umin.ac.jp/ ctr) to identify
ongoing trials.
The last update of the manual search was on 2 February 2009.
Data collection and analysis
Selection of studies
Two review authors evaluated independently all titles and abstracts
for eligibility (see Figure 1). We resolved disagreements by dis-
cussion. We applied no language restrictions. If multiple reports
described the same trial, we considered all.
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Figure 1. Flow chart
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Data collection
Two review authors (AR and EN, RS or LK) extracted trial infor-
mation independently using a standardised, piloted data extrac-
tion form accompanied by a codebook. We resolved disagreements
by consensus or discussion with a third author (SR or PJ). We ex-
tracted the type of electrostimulation, including themode of func-
tion (types of stimulator and electrode), the pulse form (intensity,
rate and width), the electrode placement site and the frequency
and duration of treatment. Other data extracted included the type
of control intervention used, patient characteristics (gender, aver-
age age, duration of symptoms, type of joint), characteristics of
pain, function and safety outcomes, design, trial size, trial duration
(defined as time from randomisation until end of follow up), type
and source of financial support and publication status. When nec-
essary, we approximated means and measures of dispersion from
figures in the reports. For cross-over trials, we extracted data from
the first period only. Whenever possible, we used results from an
intention-to-treat analysis. If effect sizes could not be calculated,
we contacted the authors for additional data.
Quality assessment
Two review authors (AR and EN, RS or LK) independently as-
sessed randomisation, blinding, selective outcome reporting and
handling of incomplete outcome data in the analyses (Higgins
2008; Jüni 2001).We resolved disagreements by consensus or dis-
cussion with a third author (SR or PJ). We assessed two compo-
nents of randomisation: generation of allocation sequences and
concealment of allocation. We considered generation of sequences
adequate if it resulted in an unpredictable allocation schedule;
mechanisms considered adequate included random-number ta-
bles, computer-generated random numbers, minimisation, coin
tossing, shuffling of cards and drawing of lots. Trials using an un-
predictable allocation sequence were considered randomised; trials
using potentially predictable allocation mechanisms, such as alter-
nation or the allocation of patients according to date of birth, were
considered quasi-randomised. We considered allocation conceal-
ment adequate if the investigators responsible for patient selection
were unable to suspect before allocation which treatment was next;
methods considered adequate included central randomisation and
sequentially numbered, sealed, opaque envelopes. We considered
blinding of patients adequate if a sham intervention was used that
was identical in appearance from the control intervention. Tran-
scutaneous electrostimulation generally does not allow blinding of
therapists, whereas pain as the main effectiveness outcome is pa-
tient-reported by definition. Therefore, we did not assess blinding
of therapists and outcome assessors. We considered handling of
incomplete outcome data adequate if all randomised patients were
included in the analysis (intention-to-treat principle). Finally, we
used GRADE to describe the quality of the overall body of evi-
dence (Higgins 2008; Guyatt 2008), defined as the extent of con-
fidence in the estimated treatment benefits and harms.
Data synthesis
We summarised continuous outcomes using standardised mean
differences (SMD), with the differences in mean values at the end
of treatment across treatment groups divided by the pooled stan-
dard deviation. If differences in mean values at the end of the
treatment were unavailable, we used differences in mean changes.
If some of the required data were unavailable, we used approxi-
mations as previously described (Reichenbach 2007). A SMD of
-0.20 standard deviation units can be considered a small differ-
ence between experimental and control group, a SMD of -0.50
a moderate difference, and -0.80 a large difference (Cohen 1988;
Jüni 2006). SMDs can also be interpreted in terms of the percent
of overlap of the experimental group’s scores with the scores of
the control group. A SMD of -0.20 indicates an overlap in the
distributions of pain or function scores in about 85% of cases,
a SMD of -0.50 in approximately 67% and a SMD of -0.80 in
about 50% of cases (Cohen 1988; Jüni 2006). On the basis of a
median pooled SD of 2.5 cm found in large-scale osteoarthritis
trials that assessed pain using a 10 cm visual analogue scale (VAS)
(Nuesch 2009), SMDs of -0.20, -0.50 and -0.80 correspond to
approximate differences in pain scores between experimental and
control groups of 0.5, 1.25 and 2.0 cm on a 10 cm VAS. SMDs
for function were back transformed to a standardised WOMAC
disability score (Bellamy 1995) ranging from 0 to 10 on the ba-
sis of a median pooled SD of 2.1 units observed in large-scale
osteoarthritis (Nuesch 2009). We expressed binary outcomes as
relative risks.
We used standard inverse-variance random-effects meta-analysis
(DerSimonian 1986) to combine trials overall and stratified ac-
cording to gross categories of electrostimulation (TENS, interfer-
ential current stimulation or pulsed electrostimulation).We quan-
tified heterogeneity between trials using the I2 statistic (Higgins
2003), which describes the percentage of variation across trials
that is attributable to heterogeneity rather than to chance and the
corresponding χ2 test. I2 values of 25%, 50% and 75% may be
interpreted as low, moderate and high between-trial heterogeneity,
although the interpretation of I2 depends on the size and number
of trials included (Rucker 2008). The association between trial
size and treatment effects was investigated in funnel plots, plot-
ting effect sizes on the vertical axis against their standard errors
on the horizontal axis. We assessed asymmetry by the asymmetry
coefficient: the difference in effect size per unit increase in stan-
dard error (Sterne 2001), which is mainly a surrogate for sam-
ple size, and used uni-variable meta-regression analysis to predict
treatment effects in trials as large as the largest trials included in
the meta-analysis, using the standard error as the explanatory vari-
able (Shang 2005). In view of the biased nature of the predom-
inantly small trials included in the meta-analysis of pain inten-
sity, we considered the predicted estimates of effectiveness more
reliable than the pooled estimates. For the analysis on the effec-
tiveness outcomes pain and function, we differentiated between
TENS, interferential current stimulation and pulsed electrostim-
ulation. Then, we performed effectiveness analyses stratified by
10Transcutaneous electrostimulation for osteoarthritis of the knee (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
the following trial characteristics: concealment of allocation, use
of a sham intervention in the control group, blinding of patients,
analysis in accordance with the intention-to-treat principle, trial
size, difference in the use of analgesic cointerventions, specific type
of electrostimulation, duration of stimulation per session, number
of sessions per week, duration of electrostimulation per week as an
overall measure of treatment intensity, and duration of treatment
period. A cut-off of 200 patients was used to distinguish between
small and large trials; a sample size of 100 patients per group will
yield more than 80% power to detect a small to moderate SMD
of -0.40 at a two-sided P of 0.05. For the analysis according to
specific type of stimulation, we distinguished between high fre-
quency TENS, burst TENS, modulation TENS, low frequency
TENS, interferential current stimulation or pulsed electrostimu-
lation. We classified conventional TENS and brief TENS as high
frequency TENS. Cut-offs of 20 and 60 minutes were used for the
duration of electrostimulation per session, corresponding to the
typical treatment duration in physical therapy, and the optimum
stimulation duration suggested by Cheing 2003. A cut-off of four
weeks was used for the overall duration of the treatment period
(time from randomisation to last session), in line with the previous
version on this review. Cut-offs of three and sevenwere used for the
number of sessions per week; one and five hours for the duration
of electrostimulation per week, corresponding to the distribution
of tertiles. We used uni-variable random-effects meta-regression
models to determine whether treatment effects were affected by
these factors (Thompson 1999). Then, we converted SMDs of
pain intensity and function to odds ratios (Chinn 2000) to derive
numbers needed to treat (NNT) to cause one additional treat-
ment response on pain or function as compared with control, and
numbers needed to harm (NNH) to cause one additional adverse
outcome. We defined treatment response as a 50% improvement
in scores (Clegg 2006), which corresponds to an average decrease
of 1.2 standard deviation units. Based on the median standardised
pain intensity at baseline of 2.4 standard deviation units and the
median standardised decrease in pain scores of 0.72 standard de-
viation units observed in large osteoarthritis trials (Nuesch 2009),
we calculated that a median of 31% of patients in the control
group would achieve an improvement of pain scores of 50% or
more. This percentage was used as the control group response rate
to calculate NNTs for treatment response on pain. Based on the
median standardised WOMAC function score at baseline of 2.7
standard deviation units and the median standardised decrease in
function scores of 0.58 standard deviation units (Nuesch 2009),
26% of patients in the control group would achieve a reduction
in function of 50% or more. Again, this percentage was used as
the control group response rate to calculate NNTs for treatment
response on function. We used median risks of 150 patients with
adverse events per 1000 patient-years, four patients with serious
adverse events per 1000 patient-years and 17 drop-outs due to
adverse events per 1000 patient-years observed in placebo groups
in large osteoarthritis trials (Nuesch 2009) to calculate NNHs for
safety outcomes. We performed analyses in RevMan version 5 (
RevMan 2008) and STATA version 10.1 (StataCorp, College Sta-
tion, Texas). All P values are two-sided.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
We identified 1697 references to articles and considered 85 to be
potentially eligible (Figure 1). Twenty-two reports describing 18
completed trials in 813 patients and two protocols describing un-
completed trials (Fary 2008; Palmer 2007) met our inclusion cri-
teria. Six trials evaluated high frequency TENS (Bal 2007; Cetin
2008; Cheing 2002; Cheing 2003; Law 2004a; Smith 1983), one
high frequency and burst TENS (Grimmer 1992), one high fre-
quency TENS and interferential current stimulation (Adedoyin
2005), one low frequency, high frequency and modulation TENS
with alternating low and high frequency current (Law 2004), one
burst TENS (Fargas-Babjak 1989), two low frequency TENS (Ng
2003; Yurtkuran 1999), four interferential current stimulation (
Adedoyin 2002; Defrin 2005; Itoh 2008; Quirk 1985), and three
evaluated pulsed electrostimulation (Fary 2008; Garland 2007;
Zizic 1995). The protocol of Palmer 2007 did not specify which
type of TENS would be used.
The description of the uncompleted trials can be found in the ’
Characteristics of ongoing studies’ table. Of the completed trials,
17 trials used a parallel group and one a 2 x 2 factorial design (
Itoh 2008). Twelve trials used a sham intervention in the control
group, five used no intervention (Adedoyin 2005; Cetin 2008;
Itoh 2008; Quirk 1985; Ng 2003) and one trial had both a sham
and a no intervention control (Cheing 2002). Standardised co-
interventions, provided in both experimental and control groups,
were used in five trials with no intervention controls (Adedoyin
2005; Cetin 2008; Cheing 2002; Ng 2003; Quirk 1985) and in
two trials with a sham intervention (Adedoyin 2002; Bal 2007).
Cetin 2008 used hot packs and exercise, Adedoyin 2002 dietary
advice and exercise,Quirk 1985, Cheing 2002 andAdedoyin 2005
exercise, Bal 2007 used infra-red therapy and Ng 2003 an educa-
tional pamphlet. In addition, Itoh 2008 assigned 50% of patients
to acupuncture using a factorial design.
Characteristics of the currents varied considerably, even within a
specific type of electrostimulation. In the three trials evaluating
low frequency TENS, pulse width and pulse frequency ranged
from 200 µsec and 2 Hz to 1000 µsec and 4 Hz, with intensities
set to reach a comfortable level in one (Law 2004), and resulting
in muscle contraction in two trials (Ng 2003; Yurtkuran 1999). In
trials of high frequency TENS, pulse width and pulse frequency
ranged from 80 µsec and 32 Hz (Smith 1983) to 200 µsec and
100 Hz (Cheing 2003), with the majority of intensities described
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as strong but comfortable. In trials of burst TENS, Fargas-Babjak
1989 used a pulse frequency of 200 Hz, a train length of 125 µsec
and a repetition frequency of 4 Hz with intensity increased up
to the patients’ limits of tolerability, while Grimmer 1992 used a
pulse frequency of 80 Hz, an unclear train length and pulse width
and a repetition frequency of 3 Hz, with the intensity resulting in
a strong, tolerable tingling sensation and visible, but comfortable
muscle contraction. In the five trials of interferential current stim-
ulation, the beat frequency ranged from 30 to 130 Hz and intensi-
ties resulted typically in tingling sensations in four trials (Adedoyin
2002; Adedoyin 2005; Itoh 2008; Quirk 1985), and pain in one (
Defrin 2005). The two trials of pulsed electrostimulation were the
only ones to use intensities below the sensory threshold (Garland
2007; Zizic 1995). The trials used the same device, which pro-
duces monophasic, spike-shaped pulses in a frequency of 100 Hz.
The intensity of the current was initially increased until a tingling
sensation was felt and subsequently reduced until this sensation
disappeared.
The trials differed in type, number and localisation of electrodes
used (see ’Characteristics of included studies’). The median du-
ration of electrostimulation per session was 25 minutes (range
15 minutes to 8.2 hours), with a duration of 15 to 20 min-
utes in 10 trials (Adedoyin 2005; Adedoyin 2002; Cetin 2008;
Cheing 2003; Defrin 2005; Itoh 2008; Quirk 1985; Ng 2003;
Smith 1983; Yurtkuran 1999), 30 to 40 minutes in six (Bal 2007;
Cheing 2003; Fargas-Babjak 1989; Grimmer 1992; Law 2004a;
Law 2004) and 60 minutes or more in 4 trials (Cheing 2002;
Cheing 2003; Garland 2007; Zizic 1995). The median number
of treatment sessions per week was 3.5 (range 1 to 14), with up to
three sessions per week in eight trials (Adedoyin 2002; Adedoyin
2005; Cetin 2008;Defrin 2005;Grimmer 1992; Itoh 2008;Quirk
1985; Smith 1983), four to six in seven (Bal 2007; Cheing 2002;
Cheing 2003; Law 2004; Law 2004a; Ng 2003; Yurtkuran 1999)
and seven or more in three trials (Fargas-Babjak 1989; Garland
2007; Zizic 1995). This resulted in a median duration of elec-
trostimulation of 1.5 hours per week (range 15 minutes to 57.4
hours). The median length of the treatment period was four weeks
(range one day to 12 weeks).
All but one trial explicitly included patients with knee osteoarthri-
tis only, with the diagnosis based on clinical and/or radiographic
evidence. Fargas-Babjak 1989 included patients with either knee
or hip osteoarthritis, and failed to report the percentage of pa-
tients with knee osteoarthritis, but it was considered likely that this
percentage was above 75%. The majority of patients had a clini-
cal severity requiring simple non-surgical treatments (Jüni 2006).
In one trial of pulsed electrostimulation, the majority of patients
(41 out of 58) were candidates for total knee arthroplasty, how-
ever (Garland 2007). The description of patient characteristics was
generally poor. Only four trials (Bal 2007; Garland 2007; Law
2004a; Yurtkuran 1999) reported the average disease duration,
which ranged from two to 8.4 years.
Four cross-over trials could not be included because of incomplete
reporting, which did not allow the distinction between treatment
phases (Lewis 1984; Lewis 1985; Lewis 1994; Taylor 1981). All
but Lewis 1985 were included in the previous version of this review
(Osiri 2000). Three other trials were excluded because of an active
control intervention using another type of electrostimulation (
Burch 2008; Jensen 1991; Volklein 1990). Detailed reasons for
exclusion are displayed in ’Characteristics of excluded studies’.
Risk of bias in included studies
Figure 2 summarises themethodological characteristics and source
of funding of included trials. One trial reported both adequate
sequence generation and adequate concealment of allocation (
Garland 2007), five trials reported only adequate sequence gener-
ation (Itoh 2008; Law 2004; Law 2004a; Ng 2003; Smith 1983)
and one trial reported adequate concealment, but provided insuf-
ficient detail on the generation of allocation sequence (Grimmer
1992). Two trials were quasi-randomised, one used alternation
to allocate patients to experimental and control intervention (
Adedoyin 2002), the other allocated patients according to hospital
registration number (Bal 2007). In the remaining nine trials, low
quality of reporting hampered any judgement regarding sequence
generation and concealment of allocation.
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Figure 2. Methodological characteristics and source of funding of included trials. (+) indicates low risk of
bias, (?) unclear and (-) a high risk of bias on a specific item.
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Six trials (Fargas-Babjak 1989;Garland2007;Grimmer1992; Law
2004; Law 2004a; Zizic 1995) were described as double-blind.
Thirteen trials used sham interventions, all using identical devices
in experimental and control groups (Adedoyin 2002; Bal 2007;
Cheing 2002; Cheing 2003; Defrin 2005; Fargas-Babjak 1989;
Garland 2007; Grimmer 1992; Law 2004a; Law 2004; Smith
1983; Yurtkuran 1999; Zizic 1995). In 10 out of 13 trials, sham
devices had broken leads so that no current could pass, whereas the
indicator light or digital display of intensity control functioned
normally. In the two pulsed electrostimulation trials, all patients
were instructed to increase the intensity until a tingling sensation
was felt, after which they were asked to reduce intensity just below
the perception (sensory) level. Pulsed electrostimulation sham de-
vices were adapted with an automatic shut-off as soon as the am-
plitude was reduced (Garland 2007; Zizic 1995). Only the sham
device used in Defrin 2005 was not considered to lead to adequate
patient blinding, as the sham device was described as shut off.
Only the two trials of pulsed electrostimulation, however, which
used currents below the sensory threshold, were deemed to have
fully credible blinding of patients (Garland 2007; Zizic 1995).
Sixteen out of 18 completed trials contributed to the analysis
of pain outcomes. Of these, only three trials (Adedoyin 2002;
Bal 2007; Grimmer 1992), which had analysed all randomly as-
signed patients, were considered to have an intention-to-treat anal-
ysis of pain outcomes at end of treatment. In three trials (Cetin
2008; Defrin 2005; Ng 2003) it was unclear whether exclusions
of randomised patients from the analysis had occurred, in five tri-
als (Fargas-Babjak 1989; Garland 2007; Law 2004; Law 2004a;
Yurtkuran 1999) exclusions were reported, but their percentage
remained unclear and in the remaining six trials the median re-
ported exclusion rate was 7% in the experimental and 11.5% in
the control groups (range 0% to 25% in both experimental and
control groups). Two out of nine trials contributing to the analysis
of function outcomes were considered to have an intention-to-
treat analysis (Bal 2007; Quirk 1985). In one trial (Cetin 2008) it
was unclear whether exclusions of randomised patients from the
analysis had occurred, in three trials (Garland 2007; Law 2004a;
Yurtkuran 1999) exclusions were reported, but their percentage
remained unclear and in the remaining three trials the median
reported exclusion rate was 11.5% in experimental and 12% in
control groups (range 0% to 25% in experimental, and 11% to
25% in control groups, respectively).
Only three trials explicitly specified primary outcomes (Adedoyin
2002; Itoh 2008; Zizic 1995), although one of these specified
more than two (Zizic 1995). Only one trial reported a sample size
calculation (Adedoyin 2005). None of the trials had a sufficient
sample size of at least 200 patients overall to achieve sufficient
power for detecting a small to moderate SMD. Only three trials
reported their source of funding: one was supported by a non-
profit organisation and a commercial body (Fargas-Babjak 1989),
the other two by a commercial body only (Garland 2007; Zizic
1995).
For the effectiveness outcomes pain and function, the quality of
the evidence (Guyatt 2008) was classified as very low in view of
the risk of bias in the included, predominantly small trials of ques-
tionable quality, the large heterogeneity between trials, the po-
tential for selective reporting of function outcomes and the ex-
ploratory nature of the model used to predict SMDs of pain in
trials as large as the largest trials (’Summary of findings for the
main comparison’). For the safety outcomes, the quality of the
evidence (Guyatt 2008) was classified as moderate to low, again
because of the predominantly small trials of questionable quality,
the small number of trials reporting the outcomes and the small
number of events resulting in imprecise estimates.
Effects of interventions
See: Summary of findings for the main comparison
Knee pain
Sixteen trials with 18 comparisons (726 patients) contributed to
the meta-analysis of pain outcomes (Figure 3). The analysis sug-
gested an overall large SMD of -0.86 (95% CI -1.23 to -0.49),
which corresponds to a difference in pain scores of 2.1 cm on
a 10 cm VAS between electrostimulation and control, favouring
electrostimulation. Within the types of electrostimulation, a very
large effect was found for interferential current stimulation (SMD
-1.20, 95% CI -1.99 to -0.42), a large effect in TENS (SMD -
0.85, 95% CI -1.36 to -0.34) and a moderate effect in pulsed elec-
trostimulation (SMD -0.41, 95% CI -0.77 to -0.05). However,
interaction tests provided little evidence for differences between
different types. Pooling all types of electrostimulation, an I2 of
80% indicated a high degree of between-trial heterogeneity (P for
heterogeneity < 0.001), which was not substantially reduced when
pooling types of electrostimulation separately. Four trials (Cheing
2003; Defrin 2005; Law 2004; Law 2004a) showed unrealistically
large SMDs of twice to three times the magnitude of what would
be expected for total joint replacement (Jüni 2006). The funnel
plot appeared asymmetrical (Figure 4, P for asymmetry < 0.001)
and the corresponding asymmetry coefficient was -7.6 (95% CI -
10.6 to -4.5). This coefficient indicates that the beneï¬t of elec-
trostimulation increases by 7.6 standard deviation units for each
unit increase in the standard error of the SMD, which is mainly a
surrogate for sample size. The predicted SMD in trials as large as
the largest trial (Zizic 1995, n = 71, standard error = 0.24) was -
0.07 (95% CI -0.46 to 0.32), which corresponds to a difference in
pain scores of 0.2 cm on a 10 cm VAS between electrostimulation
and control. Referring to a median pain intensity of 6.1 cm in
placebo groups at baseline, this corresponds to a difference of 4%
improvement (95% CI -13% to +20%) between electrostimula-
tion and control (’Summary of findings for themain comparison’).
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Figure 3. Forest plot of 16 trials comparing the effects of any type of transcutaneous electrostimulation and
control (sham or no intervention) on knee pain. Values on x-axis denote standardised mean differences. The
plot is stratified according to type of electrostimulation. Law 2004 reported on knee level, we inflated the
standard error with sqrt(number knees)/sqrt(number patients) to correct for clustering of knees within
patients. Adedoyin 2005 and Cheing 2002 contributed with two comparisons each. In Adedoyin 2005, the
standard error was inflated and the number of patients in the control group was halved to avoid duplicate
counting of patients when including 2 both comparisons in the overall meta-analysis. Data relating to the 3, 2,
3 and 4 active intervention arms in Cheing 2003, Grimmer 1992, Law 2004 and Defrin 2005, respectively, were
pooled.
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Figure 4. Funnel plot for effects on knee pain.
Numbers on x-axis refer to standardised mean differences (SMDs), on y-axis to standard errors of SMDs.
Table 1 presents results from stratified analyses. Estimates of SMD
varied to some degree depending on concealment of allocation,
adequacy of patient blinding, use of analgesic cointerventions and
characteristics of electrostimulation, but 95% CIs of SMDs were
wide and tests of interaction and tests for trend not statistically sig-
nificant. There was little evidence to suggest that SMDs depended
on the type of electrostimulation used (P for interaction = 0.94).
Contrary to what would be expected in the presence of relevant
placebo effects, we found some evidence towards larger benefits
of electrostimulation in trials with a sham intervention as com-
pared with trials without (P for interaction = 0.12). In addition,
there was some evidence for larger benefits of electrostimulation
associated with short durations of the overall treatment period of
less than four weeks as compared with four weeks or more (P for
interaction = 0.14). The analysis could not be stratified according
to sample size, because none of included trials reached the pre-
specified sample size of 200 patients to be considered as adequately
sized.
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Table 1. Results of stratified analyses of pain outcomes
Variable N of trials N of patients
(experimental)
N of patients
(control)
Pain intensity Heterogeneity P for interaction
n n n SMD (95% CI) I2 (%)
All trials 16 440 286 -0.86 (-1.23 to -
0.49)
80%
Allocation con-
cealment
0.47
Adequate 2 79 39 -0.52 (-0.91 to -
0.13)
0%
Inadequate or
unclear
14 361 247 -1.03 (-1.49 to -
0.57)
84%
Type of control
intervention*
0.12
Sham interven-
tion
12 354 216 -1.13 (-1.59 to -
0.67)
82%
No control inter-
vention
5 86 70 -0.31 (-0.80 to
0.19)
58%
Blinding of pa-
tients
0.37
Adequate 11 309 205 -1.05 (-1.52 to -
0.59)
82%
Inadequate or
unclear
6 131 79 -0.63 (-1.31 to
0.05)
81%
Use of analgesic
cointerventions
0.36
Similar between
groups
4 124 83 -0.57 (-1.16 to
0.02)
74%
Not similar or
unclear
12 316 23 -1.10 (-1.60 to -
0.59)
84%
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Table 1. Results of stratified analyses of pain outcomes (Continued)
Intention-to-
treat analysis
0.73
Yes 3 83 63 -0.76 (-1.43 to -
0.09)
72%
No or unclear 13 357 223 -1.00 (-1.48 to -
0.53)
84%
Type of ES** 0.94
High frequency
TENS
8 177 139 -0.82 (-1.51 to -
0.12)
86%
Burst TENS 2 39 38 -0.85 (-1.32 to -
0.38)
0%
Modulation
TENS
1 13 3 -1.41 (-2.92 to
0.10)
N/A
Low frequency
TENS
3 46 40 -0.82 (-1.29 to -
0.34)
0%
Interferen-
tial current stim-
ulation
4 88 44 -1.20 (-1.99 to -
0.42)
71%
Pulsed ES 2 77 52 -0.41 (-0.77 to -
0.05)
0%
Duration of ES
per session†
0.69‡
≤ 20 minutes 8 166 112 -0.95 (-1.55 to -
0.35)
78%
30 to 40 minutes 6 156 99 -1.45 (-2.28 to -
0.62)
85%
≥ 60 minutes 4 118 91 -0.47 (-0.96 to
0.02)
58%
Number of ses-
sions per week
0.90‡
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Table 1. Results of stratified analyses of pain outcomes (Continued)
≤ 3 6 163 91 -0.81 (-1.48 to -
0.14)
82%
4 to 6 7 182 125 -1.33 (-2.11 to -
0.54)
88%
≥ 7 3 96 70 -0.51 (-0.83 to -
0.19)
0%
Duration of ES
per week***
0.74‡
≤1 hour 5 123 71 -0.85 (-1.72 to
0.01)
86%
> 1 to 5 hours 8 180 122 -1.42 (-2.11 to -
0.74)
81%
> 5 hours 5 137 109 -0.53 (-0.96 to -
0.11)
55%
Duration
of treatment pe-
riod
0.14
< 4 weeks 7 190 114 -1.39 (-2.13 to -
0.66)
86%
≥ 4 weeks 9 250 172 -0.64 (-1.06 to -
0.22)
75%
ES: electrostimulation; *In Cheing 2002, two independent comparisons contributed in the two different strata. **Adedoyin 2005,
Grimmer 1992 and Law 2004 contributed to two, two and three different strata: high-frequency TENS and interferential current
stimulation, high-frequency TENS and burst, and high-, low-frequency and modulation TENS, respectively. † = Cheing 2003
contributed to all three different strata, with the same 8 control patients displayed in each stratum. ‡ = P values from test for trend.
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Withdrawals or drop-outs because of adverse events
Eight trials (348 patients) contributed to the meta-analysis of pa-
tients withdrawn or dropped out because of adverse events (Figure
5). Of these, four TENS trials and one interferential current stim-
ulation trial reported that no withdrawals or drop-outs due to ad-
verse events had occurred, neither in experimental nor in control
groups, therefore relative risks could not be estimated. In the re-
maining three trials, there was no evidence that transcutaneous
electrostimulation is unsafe (relative risk 0.97), but 95% confi-
dence intervals were wide and ranged from 0.16 to 6.00. Pooling
all types of electrostimulation, an I2 of 20% indicated a low degree
of between-trial heterogeneity (P for heterogeneity = 0.29).
Figure 5. Forest plot of 8 trials comparing patients withdrawn or dropped out because of adverse events
between any transcutaneous electrostimulation and control (sham or no intervention). Values on x-axis
denote risk ratios. Risk ratios could not be estimated in 5 trials, because no drop-out occurred in either group.
The plot is stratified according to type of electrostimulation. Data relating to the 3 and 2 active intervention
arms in Cheing 2003 and Grimmer 1992, respectively, were pooled.
Function
Nine trials (407 patients) contributed to themeta-analysis of func-
tion. The analysis suggested a small SMD of -0.34 (95% CI -
0.54 to -0.14, Figure 6), which corresponds to a difference in
function scores of 0.7 units on a standardised WOMAC disability
scale ranging from 0 to 10, favouring electrostimulation. Refer-
ring to a median function score of 5.6 units in placebo groups
at baseline, this corresponds to a difference of 20% improvement
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(95% CI +11% to +29%) between electrostimulation and con-
trol (’Summary of findings for the main comparison’). The esti-
mated difference in the percentage of treatment responders be-
tween patients allocated to electrostimulation and patients allo-
cated to placebo of 3% translated into an NNT to cause one ad-
ditional treatment response on function of 29 (95% CI 19 to 69)
(’Summary of findings for the main comparison’). Differences be-
tween types of electrostimulation were not statistically significant.
An I2 of 0% suggested no between-trial heterogeneity (P for het-
erogeneity = 0.57). The funnel plot did not appear asymmetrical (
Figure 7, P for asymmetry = 0.52). The corresponding asymmetry
coefficient was 1.4 (95% CI, -3.5 to 6.3).
Figure 6. Forest plot of 9 trials comparing the effects of any type of transcutaneous electrostimulation and
control (sham or no intervention) on function. Values on x-axis denote standardised mean differences. The
plot is stratified according to type of electrostimulation. In Adedoyin 2005, the standard error was inflated and
the number of patients in the control group was halved to avoid duplicate counting of patients when including
both comparisons in the overall meta-analysis.
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Figure 7. Funnel plot for effects on functioning of the knee.
Numbers on x-axis refer to standardised mean differences (SMDs), on y-axis to standard errors of SMDs.
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Table 2 presents results from stratified analyses. Estimates of SMD
varied to some degree depending on type of control intervention,
adequacy of patient blinding, characteristics of electrostimulation
and overall treatment period, but 95%CIs of SMDswere wide and
tests for interaction and tests for trend not statistically significant.
There was little evidence to suggest that SMDs depended on the
type of electrostimulation used (P for interaction = 0.32). Again,
the analysis could not be stratified according to sample size, because
none of included trials reached the pre-specified sample size of 200
patients to be considered as adequately sized.
Table 2. Results of stratified analyses of function
Variable N of trials N of patients
(experimental)
N of patients
(control)
Function Heterogeneity P for interaction
SMD (95% CI) I2 (%)
All trials 9 226 181 -0.34 (-0.54 to -
0.14)
0%
Allocation con-
cealment
0.88
Adequate 1 39 19 -0.29 (-0.85 to
0.26)
N/A
Inadequate or
unclear
8 187 162 -0.34 (-0.56 to -
0.12)
5%
Type of control
intervention
0.14
Sham interven-
tion
5 151 120 -0.46 (-0.70 to -
0.21)
0%
No control inter-
vention
4 75 61 -0.10 (-0.45 to
0.24)
0%
Blinding of pa-
tients
0.14
Adequate 5 151 120 -0.46 (-0.70 to -
0.21)
0%
Inadequate or
unclear
4 75 61 -0.10 (-0.45 to
0.24)
0%
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Table 2. Results of stratified analyses of function (Continued)
Use of analgesic
cointerventions
0.95
Similar between
groups
2 69 48 -0.33 (-0.70 to
0.05)
0%
Not similar or
unclear
7 157 133 -0.34 (-0.60 to -
0.08)
15%
Intention-to-
treat analysis
0.76
Yes 2 40 42 -0.28 (-0.71 to
0.16)
0%
No or unclear 7 186 139 -0.35 (-0.58 to -
0.12)
5%
Type of ES** 0.32
High frequency
TENS
4 84 70 -0.18 (-0.50 to
0.14)
0%
Burst TENS 0
Modulation
TENS
0
Low frequency
TENS
1 25 25 -0.88 (-1.46 to -
0.30)
N/A
Interferen-
tial current stim-
ulation
3 40 34 -0.27 (-0.75 to
0.20)
0%
Pulsed ES 2 77 52 -0.36 (-0.72 to -
0.00)
0%
Duration of ES
per session
0.80‡
≤ 20 minutes 5 100 86 -0.29 (-0.69 to
0.11)
44%
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Table 2. Results of stratified analyses of function (Continued)
30 to 40 minutes 2 49 43 -0.37 (-0.79 to
0.04)
0%
≥ 60 minutes 2 77 52 -0.36 (-0.72 to -
0.00)
0%
Number of ses-
sions per week
0.32‡
≤ 3 4 75 61 -0.10 (-0.45 to
0.24)
0%
4 to 6 3 74 68 -0.54 (-0.88 to -
0.20)
2%
≥ 7 2 77 52 -0.36 (-0.72 to -
0.00)
0%
Duration of ES
per week
0.32‡
≤ 1 hour 4 75 61 -0.10 (-0.45 to
0.24)
0%
> 1 to 5 hours 3 74 68 -0.54 (-0.88 to -
0.20)
2%
> 5 hours 2 77 52 -0.36 (-0.72 to -
0.00)
0%
Duration
of treatment pe-
riod
0.18
< 4 weeks 3 74 68 -0.54 (-0.88 to -
0.20)
2%
≥ 4 weeks 6 152 113 -0.23 (-0.47 to
0.02)
0%
ES: electrostimulation; **Adedoyin 2005 contributed to two different strata: high-frequency TENS and interferential current stimu-
lation; ‡ = P values from test for trend.
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Other safety outcomes
Three trials (175 patients) contributed to the meta-analysis of
patients experiencing any adverse event (Figure 8) and four trials
(195 patients) to the meta-analysis of patients experiencing any
serious adverse event (Figure 9). In general, there was no evidence
to suggest that electrostimulation is unsafe, but 95% CIs were
wide and results inconclusive.
Figure 8. Forest plot of 3 trials comparing patients experiencing any adverse event between any
transcutaneous electrostimulation and control (sham or no intervention). Values on x-axis denote risks ratios.
The risk ratio in one TENS trial could not be estimated because no adverse event occurred in either group.
The plot is stratified according to type of electrostimulation.
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Figure 9. Forest plot of 4 trials comparing patients experiencing any serious adverse event between any
transcutaneous electrostimulation and control (sham or no intervention). Values on x-axis denote risk ratios.
Risk ratios could not be estimated in 3 trials, because no serious adverse event occurred in either group. The
plot is stratified according to type of electrostimulation. Data relating to the 3 active intervention arms in
Cheing 2003 were pooled.
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D I S C U S S I O N
Summary of main results
Our systematic review of trials comparing any type of transcuta-
neous electrostimulation with a sham or non-intervention con-
trol revealed a lack of adequately sized, methodologically sound
and appropriately reported trials and a moderate to high degree
of heterogeneity between trials, which made the interpretation of
results difficult, particularly for joint pain as the primary therapeu-
tic target of transcutaneous electrostimulation. In an attempt to
minimise biases associated with small trials of questionable qual-
ity, we used meta-regression to predict effects of transcutaneous
electrostimulation on pain and found the predicted effect sizes for
pain negligibly small. The rates of withdrawals or drop-outs due
to adverse events were comparable in experimental and control
groups, but 95% CIs were wide and therefore inconclusive.
Quality of the evidence
An inspection of funnel plots and a formal analysis of asymmetry
indicated asymmetry for knee pain, but not for function, which
suggested the presence of biases associated with small sample size
particularly when estimating the effects of electrostimulation on
knee pain. Asymmetrical funnel plots should be seen not only as
an indication of publication bias, but as a generic tool for exami-
nation of small study effects: the tendency for the smaller studies
to show larger treatment effects, possibly due to a combination of
publication bias, selective reporting of outcomes andmethodolog-
ical problems particularly in small trials (Nuesch 2009a; Sterne
2000). If reporting is inadequate, as was the case in our systematic
review, then the standard error as a proxy for study size may be a
more precise measure of trial quality than formal assessments of
methodological quality. When modelling effects expected in trials
as large as the largest trial included in our systematic review, we
found effects on pain near null -0.07 (95% CI -0.46 to 0.32),
which were clearly smaller than the pooled SMD actually found
for pain in the meta-analysis -0.86 (95% CI -1.23 to -0.49). The
effect of electrostimulation on function was small, but potentially
clinically relevant, and the accumulated evidence appeared less af-
fected by biases associated with small sample size.
The methodological quality and the quality of reporting was poor.
Insufficient information was noted in several randomised con-
trolled trials about the treatment assignment procedure and con-
cealment of allocation. Primary outcomes were specified in only
three trials. Although several studies reported blinding of patients,
complete blinding is difficult to achieve due to the sensory differ-
ences between treatment and placebo, as well as unintended com-
munication between patient and evaluator (Deyo 1990). Only
Grimmer 1992 and Bal 2007 mentioned the inclusion of patients
to be restricted to those without prior TENS experience; another
two trials were likely to have achieved adequate blinding of pa-
tients with currents below the sensory threshold used in the ex-
perimental group, which were likely to be indistinguishable from
the sham intervention also for patients with treatment experience
(Garland 2007, Zizic 1995). The majority of papers did not pro-
vide adequate information regarding withdrawals, drop-outs and
losses to follow up, nor indicated whether patients with incom-
plete clinical data were included in the data analysis. Several trials
omitted to describe adverse events, which is of concern.
Potential biases in the review process
Our review is based on a broad literature search, and it seems un-
likely that we missed relevant trials. Trial selection and data ex-
traction, including quality assessment, were done independently
by two authors to minimise bias and transcription errors. Com-
ponents used for quality assessment are validated and reported to
be associated with bias (Jüni 2001; Wood 2008).
As with any systematic review, our study is limited by the qual-
ity of included trials. As indicated above, trials generally suffered
from poor methodological quality, inadequate reporting and small
sample size. Some trials (Cheing 2003; Defrin 2005; Law 2004a)
showed unrealistically large SMDs of twice to three times themag-
nitude of what would be expected for total joint replacement (
Jüni 2006). Including these trials in the meta-analysis is likely to
result in an overestimation of the benefits of transcutaneous elec-
trostimulation.
Agreements and disagreements with other
studies or reviews
Interestingly, there are nearly asmany systematic reviews andmeta-
analyses on transcutaneous electrostimulation in osteoarthritis as
randomised trials. Here, we will focus mainly on the similarities
and differences between ours and the previous version of this re-
view (Osiri 2000), which included seven transcutaneous electrical
nerve stimulation (TENS) trials. We updated the search and used
broader selection criteria, which resulted in 14 additional trials;
11 trials used TENS as the experimental treatment, four inter-
ferential current stimulation, one both TENS and interferential
current stimulation, and two pulsed electrostimulation. As in the
review of Osiri 2000, both parallel group and cross-over RCTs
were included. For the cross-over studies, we only collected data
from the first intervention phase in order to eliminate carry-over
effects, whereas Osiri and colleagues included pooled data over all
phases. We excluded three previously included cross-over trials,
because the investigators were unable to provide data from the first
phase only. In this update, we performed a more detailed quality
assessment of component trials, followed by a detailed exploration
of sources of variation between trials, including concealment of
allocation, blinding, intention-to-treat analysis, characteristics of
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electrostimulation, and the investigation of funnel plots. To anal-
yse continuous data, Osiri and colleagues used weighted mean
differences or SMDs of the change from baseline scores, whereas
we used SMDs of end of treatment scores and based our conclu-
sions on treatment effects on pain predicted in uni-variable meta-
regression models by using the standard error as the explanatory
variable. In addition, fixed-effect models were used in the previ-
ous version unless there was statistically significant heterogeneity
between trials based on χ2 testing. Model selection based on the
mechanistic application of heterogeneity tests should be avoided,
however. Here, we used random-effects models, which will gen-
erally be more conservative in terms of the estimated precision,
but will be more affected by small study effects than a fixed-ef-
fect model, which makes an exploration of sources of variation,
including different types of bias, mandatory. Results from the pre-
vious and current versions are therefore not directly comparable.
Nevertheless, pooled SMDs for pain were favourable in our and
the previous review (Osiri 2000), with us reporting a pooled SMD
of -0.86 (95% CI -1.23 to -0.49), whereas Osiri 2000 reported a
SMD of -0.45 (95% CI -0.70 to -0.19), with confidence intervals
overlapping widely. Although both Osiri and we acknowledge the
risk of bias in summary estimates, Osiri concluded that transcuta-
neous electrostimulation is “shown to be effective in pain control
over placebo”. We disagree with these conclusions: when mod-
elling effects expected in trials as large as the largest trial included,
we found the SMD of pain near null and clinically irrelevant (-
0.07, 95% CI -0.46 to 0.32). Osiri 2000 recorded function sep-
arately for the outcomes ’stiffness of the knee’, ’50-foot walking
time’, ’quadriceps muscle strength’ and ’knee flection’ with only
one trial contributing to each of the categories. We choose a dif-
ferent approach, using a hierarchy developed to minimise the im-
pact of selective reporting of outcomes and to allow for a synthesis
of evidence across different studies using divergent definitions of
function. Our effect sizes and conclusion concerning function are
less favourable compared to those made by Osiri 2000. In this
version, we also summarised safety data and found no evidence
to suggest that electrostimulation is unsafe. Finally, unlike Osiri
2000, we also included trials of interferential current stimulation
and pulsed electrostimulation. One of the two trials of pulsed elec-
trostimulation (Zizic 1995) is covered in another Cochrane Re-
view by Hulme 2002 on electromagnetic fields, even though the
device used (BioniCare BIO-1000) does not generate electromag-
netic fields, but electric currents (Regence Medical Policy 2009).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Despite more than 20 years of clinical research, there is a lack of
adequate evidence to support the use of any type of transcutaneous
electrostimulation in patients with knee osteoarthritis. The effects
on both knee pain and function are potentially clinically relevant
and deserve further clinical evaluation.
Implications for research
The current systematic review is inconclusive, hampered by the in-
clusion of only small trials of questionable quality (Nuesch 2009a).
Adequately sized randomised parallel-group trials in about 2 x
100 patients with knee osteoarthritis are necessary to determine
whether a specific type of transcutaneous electrostimulation is in-
deed associated with a clinically relevant benefit on pain. A sample
size of 2 x 100 patients will yield more than 80% power to detect
a small to moderate SMD of -0.40 at a two-sided P of 0.05, which
corresponds to a difference of 1 cm on a 10 cm visual analogue
scale (VAS) between experimental and control intervention. The
trials should enrol patients without prior experience of any type of
transcutaneous electrostimulation or evaluate success of blinding
at the end of trial, use adequate concealment of allocation, experi-
mental and sham interventions that are close to indistinguishable
and an intention-to-treat analysis. Transcutaneous electrical nerve
stimulation (TENS) devices are marketed as small, inexpensive,
easy-to-use home units, but in the majority of trials TENS was
administered by a therapist in a practice or hospital setting. Fu-
ture research may focus on the effectiveness of self-administered
TENS, with accurate recording of the duration of electrostimu-
lation per day to assess compliance and enable the exploration of
possible dose-effect relationships.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Adedoyin 2002
Methods Quasi-randomised trial using alternation for the allocation of patients
2-arm parallel group design
Trial duration: 4 weeks
No power calculation reported
Participants 30 patients randomised
30 patients with knee OA reported at baseline
Study joints: 30 knees
Number of females: 20 of 30 (67%)
Average age: 59 years
Average BMI: 28 kg/m2
Interventions Experimental intervention: interferential current stimulation, dietary advice and exercise,
twice per week
Control intervention: Sham interferential current stimulation, dietary advice and exer-
cise, twice per week
Duration of treatment period: 4 weeks
Analgesics not allowed
Device: Enraf-Nonius Endomed 5921 (4 pole)
Self-administered: no
Waveform: interferential
Pulse width: not applicable
Pulse frequency: amplitude-modulated frequency of 100Hz for 15min (beat frequency),
80 Hz for last 5 min (beat frequency)
Amplitude: above sensory threshold, up to appreciable sensation
Duration of stimulation per session: 20 minutes
Electrodes: 4 electrodes covered with padding
Placement: 2 latero-medial, 2 antero-posterior
Outcomes Extracted pain outcome: global pain after 4 weeks, described as “Pain perception (VAS)”
No function outcome reported
Primary outcome: global pain (VAS)
Notes All subjects from black Nigerian population
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? No Alternation
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Adedoyin 2002 (Continued)
Allocation concealment? No Alternation
Free of selective reporting? Unclear Trial protocol not accessible, methods section not explicit about
pre-specified outcomes
Adequate blinding of patients? Yes Sham device: identical in appearance, not increasing intensity,
flash light on, patient in position unable to read level of intensity
Incomplete outcome reporting: intention-
to-treat analysis performed?
Pain
Yes -
Incomplete outcome reporting: intention-
to-treat analysis performed?
Function
Unclear Not applicable, no function outcome reported
Funding by commercial organisation
avoided?
Unclear No information provided
Funding by non-profit organisation? Unclear No information provided
Adedoyin 2005
Methods Randomised controlled trial
3-arm parallel group design
Trial duration: 4 weeks
Power calculation reported
Participants 51 patients randomised
46 patients with knee OA reported at baseline
Study joints: 46 knees
Number of females: 28 of 46 (61%)
Average age: 55 years
Average BMI: 28 kg/m2
Interventions Comparison 1
Experimental intervention: TENS and exercise twice per week
Control intervention: exercise, twice per week
Comparison 2
Experimental intervention: interferential current stimulation and exercise, twice per
week
Control intervention: exercise, twice per week
Duration of treatment period: 4 weeks
Analgesics not allowed, patients confirmed not to take analgesics
TENS Device: Endomed 5921D
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Adedoyin 2005 (Continued)
Self-administered: no
Waveform: not reported
Pulse width: 200 ms
Pulse frequency: 80 Hz
Amplitude: above sensory threshold, strong but comfortable
Duration of stimulation per session: 20 minutes
Electrodes: 2 electrodes 8 x 6 cm
Placement: Each side of affected knee joint, aligned longitudinally along length of limb
Interferential Current Stimulation Device: Endomed 5921D (2 pole)
Waveform: interferential
Pulse width: not applicable
Pulse frequency: 80 Hz (beat)
Amplitude: above sensory threshold: strong but comfortable, strong tingling sensation
without muscle contraction
Duration of stimulation per session: 20 minutes
Electrodes: 2 electrodes 8 x 6 cm
Placement: each side of affected knee joint, aligned longitudinally along length of limb
Outcomes Extracted pain outcome: pain on activities other than walking after 4 weeks, described as
“Pain recorded while standing (10-point pain rating scale with 0 “no pain”, 5 “moderate
pain” and 10 “worst pain imaginable”)”
Extracted function outcome: WOMAC global scale after 4 weeks (Likert)
No primary outcome reported
Notes -
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No information provided
Allocation concealment? Unclear No information provided
Free of selective reporting? Unclear Trial protocol not accessible, methods section not explicit about
pre-specified outcomes
Adequate blinding of patients? No No sham intervention
Incomplete outcome reporting: intention-
to-treat analysis performed?
Pain
No 15 out of 15 (100%) in TENS group, 16 out of 19 (84%) in
interferential current stimulation group, 15 out of 17 (88%) in
control group analysed
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Adedoyin 2005 (Continued)
Incomplete outcome reporting: intention-
to-treat analysis performed?
Function
No See above
Funding by commercial organisation
avoided?
Unclear No information provided
Funding by non-profit organisation? Unclear No information provided
Bal 2007
Methods Quasi-randomised single centre controlled trial with allocation according to hospital
registration number
2-arm parallel group design
Trial duration: 13 weeks
No power calculation reported
Participants 56 patients randomised
56 patients with knee OA reported at baseline
Study joints: 56 knees
Number of females: 50 of 56 (89%)
Average age: 57 years
Average BMI: 31 kg/m2
Average disease duration: 2 years
Interventions Experimental intervention: TENS and infra-red therapy, 5 times per week
Control intervention: sham TENS and infra-red therapy, 5 times per week
Duration of treatment period: 2 weeks
Unclear whether analgesics were allowed and the intake was assessed
Device: PlusMED 1-904
Self-administered: no
Waveform: not reported
Pulse width: 140 µsec
Pulse frequency: 80 Hz
Amplitude: above sensory threshold, not up to maximum tolerance, no muscle contrac-
tions observed*
Duration of stimulation per session: 40 minutes
Electrodes: 4, type unclear
Placement: acupuncture points: ST36, GB34, SP10, SP9, ST34
Outcomes Extracted pain outcome: WOMAC pain subscore after 13 weeks (Likert)
Extracted function outcome: WOMAC disability subscore after 13 weeks (Likert)
No primary outcome reported
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Bal 2007 (Continued)
Notes Article in Turkish, outcome assessment done by AR and RS assisted by a native Turkish
researcher. Serpil Bal verified all extracted data. *as indicated by Serpil Bal in personal
communication.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? No The published report only stated that there was a random allo-
cation of patients to comparison groups. In personal communi-
cation, investigator Serpil Bal stated that the patients were allo-
cated according to last digit of their hospital registration num-
ber. Patients with even numbers were assigned to TENS group,
patients with odd numbers to a sham intervention.
Allocation concealment? No No, the same investigator responsible of randomisation was giv-
ing interventions, as indicated by Serpil Bal in personal com-
munication
Free of selective reporting? Unclear Trial protocol not accessible, methods section not explicit about
pre-specified outcomes, we have been unable to sort out this
item with investigator Serpil Bal
Adequate blinding of patients? Yes Trial is described as single blind study using sham device
PlusMED 1-904, indistinguishable from real TENS unit. Sham
device had broken leads, no current passed but flashing light was
on. None of the patients had prior experience with TENS.
Incomplete outcome reporting: intention-
to-treat analysis performed?
Pain
Yes All subjects were available for end of treatment measurements,
as indicated by Serpil Bal in personal communication
Incomplete outcome reporting: intention-
to-treat analysis performed?
Function
Yes All subjects were available for end of treatment measurements,
as indicated by Serpil Bal in personal communication
Funding by commercial organisation
avoided?
Unclear No information provided
Funding by non-profit organisation? Unclear No information provided
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Cetin 2008
Methods Randomised controlled trial
5-arm parallel group design
Trial duration: 8 weeks
No power calculation reported
Participants 100 patients randomised
100 patients with knee OA reported at baseline
Study joints: 100 knees
Number of females: 100 of 100 (100%)
Average age: 60 years
Average BMI: 28 kg/m2
Interventions Experimental intervention: TENS + hot packs + isokinetic exercise, 3 times per week
Control intervention: hot packs + isokinetic exercise, 3 times per week
Duration of treatment period: 8 weeks
Analgesics allowed, unclear whether intake was similar between groups
Device: MED911
Self-administered: no
Waveform: not reported
Puls width: 60 msecs
Pulse frequency: 60-100 Hz
Amplitude: above sensory threshold, increased to point of seeing no contraction, while
patient felt comfortable
Duration of stimulation per session: 20 minutes
Electrodes: not reported
Electrode placement: around painful areas
Outcomes Extracted pain outcome: pain on walking after 8 weeks, described as “Knee pain severity
after a 50-m walk (VAS)”
Extracted function outcome: Lequesne OA index global score after 8 weeks (Likert)
No primary outcome reported
Notes Only 2 arms qualified for inclusion in this review
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No information provided
Allocation concealment? Unclear No information provided
Free of selective reporting? Unclear Trial protocol not accessible, methods section not explicit about
pre-specified outcomes
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Cetin 2008 (Continued)
Adequate blinding of patients? No No sham intervention
Incomplete outcome reporting: intention-
to-treat analysis performed?
Pain
Unclear No information provided
Incomplete outcome reporting: intention-
to-treat analysis performed?
Function
Unclear No information provided
Funding by commercial organisation
avoided?
Unclear No information provided
Funding by non-profit organisation? Unclear No information provided
Cheing 2002
Methods Randomised controlled trial
4-arm parallel group design
Trial duration: 8 weeks
Randomisation stratified according to age, gender, BMI
No power calculation reported
Participants 66 patients randomised
62 patients with knee OA reported at baseline
Study joints: 62 knees
Number of females: 53 of 62 (85%)
Average age: 64 years
Average BMI: 28 kg/m2
Interventions Comparison 1
Experimental intervention: 60 min TENS, 5 times per week
Control intervention: sham TENS, 5 times per week
Comparison 2
Experimental intervention: TENS plus exercise, 5 times per week
Control intervention: exercise alone, 5 times per week
Duration of treatment period: 4 weeks
Analgesics allowed, unclear whether intake was similar between groups
Device: MAXIMA III (dual channel)
Self-administered: unclear, most likely not
Waveform: square
Pulse width: 140 µsec
Pulse frequency: 80 Hz
Amplitude: above sensory threshold, tingling sensation, 3 to 4 times above sensory
threshold
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Cheing 2002 (Continued)
Duration of stimulation per session: 60 minutes
Electrodes: 4 electrodes of 4 x 4 cm
Placement: at acupuncture points: ST35, SP9,GB34, extra 31,32 (one electrode covering
both extra 32 and ST35)
Outcomes Extracted pain outcome: global pain after 8 weeks, described as “Intensity of subjective
pain sensation (Baseline score on 0-10 cm VAS was standardised to be 100% in each of
the groups. Follow up values were expressed as mean decrease in % from baseline)”.
No function outcome reported
No primary outcome reported
Notes -
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No information provided
Allocation concealment? Unclear No information provided
Free of selective reporting? Unclear Trial protocol not accessible, methods section not explicit about
pre-specified outcomes
Adequate blinding of patients? Yes Comparison 1: Yes, sham device identical in appearance to real
TENS unit, no current passed but indicator light was lit up
Comparison 2: No, no sham intervention
Incomplete outcome reporting: intention-
to-treat analysis performed?
Pain
No Comparison1: 16out of 16 (100%) randomised to experimental
and 16 out of 18 (89%) randomised to control group were
analysed
Comparison 2: 15 out of 17 (88%) randomised to experimental
and 15 out of 15 (100%) randomised to control group were
analysed
Incomplete outcome reporting: intention-
to-treat analysis performed?
Function
Unclear Not applicable
Funding by commercial organisation
avoided?
Unclear No information provided
Funding by non-profit organisation? Unclear No information provided
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Cheing 2003
Methods Randomised controlled trial
4-arm parallel group design
Trial duration: 4 weeks
Randomisation stratified according to gender
No power calculation reported
Participants 40 patients randomised
38 patients with knee OA reported at baseline
Study joints: 38 knees
Number of females: 34 of 38 (89%)
Average age: 66 years
Interventions Experimental intervention: 20 min TENS in group 1, 40 min TENS in group 2, 60
min TENS in group 4, 5 times per week
Control intervention: sham TENS, 5 times per week
Duration of treatment period: 2 weeks
Unclear whether analgesics were allowed and whether intake was similar between groups
Device: ITO 120Z TENS (dual channel)
Self-administered: no
Waveform: not reported
Pulse width: 200 µsec
Pulse frequency: 100 Hz
Amplitude: above sensory threshold, strong but comfortable
Duration of stimulation per session: 20 minutes
Electrodes: 4 of 2 x 3 cm rubber electrodes
Placement: 4 acupuncture points extra 31,32, ST35, GB34, SP9
Outcomes Extracted pain outcome: pain onwalking after 4weeks, described as “pain duringwalking
(VAS)”
No function outcome reported
No primary outcome reported
Notes -
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No information provided
Allocation concealment? Unclear No information provided
Free of selective reporting? Unclear Trial protocol not accessible, methods section not explicit about
pre-specified outcomes
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Cheing 2003 (Continued)
Adequate blinding of patients? Yes Sham device: electronic circuit disconnected, no current passed,
but indicator light on
Incomplete outcome reporting: intention-
to-treat analysis performed?
Pain
No 30 out of 30 (100%) randomised to experimental and 8 out of
10 (80%) randomised to control group were analysed
Incomplete outcome reporting: intention-
to-treat analysis performed?
Function
Unclear Not applicable
Funding by commercial organisation
avoided?
Unclear No information provided
Funding by non-profit organisation? Unclear No information provided
Defrin 2005
Methods Randomised controlled trial
6-arm parallel group design
Trial duration: 4 weeks
No power calculation reported
Participants 62 patients randomised
62 patients with knee OA reported at baseline
Study joints: 62 knees
Average age: 67 years
Interventions Experimental intervention: noxious adjusted interferential current stimulation in group
1, noxious unadjusted interferential current stimulation in group 2, innocuous adjusted
interferential current stimulation in group 3, innocuous unadjusted interferential current
stimulation in group 4, 3 times per week
Control intervention: sham interferential current stimulation, 3 times per week
Duration of treatment period: 4 weeks
Analgesics allowed, unclear whether intake was similar between groups.
Device: Uniphy: Phyaction electrical stimulator
Self-administered: no
Waveform: interferential
Pulse width: not applicable
Pulse frequency: 30 to 60 Hz (beat)
Amplitude: above sensory threshold, 2 groups 30% above pain threshold; 2 groups 30%
below pain threshold
Duration of stimulation per session: 20 minutes
Electrodes: 2 of 8 x 6 cm wet sponge electrodes
Placement: medial and lateral aspects of the knee, 2 cm from outer margins of patella
44Transcutaneous electrostimulation for osteoarthritis of the knee (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Defrin 2005 (Continued)
Outcomes Extracted pain outcome: global pain after 4 weeks, described as “chronic pain intensity
(VAS)”
No function outcome reported
No primary outcome reported
Notes 1 out of 6 trial arms, the no-intervention control group was excluded in the review
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No information provided
Allocation concealment? Unclear No information provided
Free of selective reporting? Unclear Trial protocol not accessible, methods section not explicit about
pre-specified outcomes
Adequate blinding of patients? Unclear Use of sham device: Uniphy-Phyaction electrical stimulator,
however the device described as shut-off
Incomplete outcome reporting: intention-
to-treat analysis performed?
Pain
Unclear No information provided
Incomplete outcome reporting: intention-
to-treat analysis performed?
Function
Unclear Not applicable
Funding by commercial organisation
avoided?
Unclear No information provided
Funding by non-profit organisation? Unclear No information provided
Fargas-Babjak 1989
Methods Randomised controlled trial
2-arm parallel group design
Trial duration: 13 weeks
No power calculation reported
Participants 56 patients randomised
56 patients with knee OA reported at baseline
Study joints: 56 joints, most likely > 75% knees
45Transcutaneous electrostimulation for osteoarthritis of the knee (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Fargas-Babjak 1989 (Continued)
Average age; gender, BMI: not reported
Interventions Experimental intervention: burst TENS, twice per day
Control intervention: sham TENS, twice per day
Duration of treatment period: 6 weeks
Analgesics allowed, but change of dosage prohibited. Unclear whether analgesics were
assessed and whether intake was similar between groups.
Device: Codetron
Self-administered: yes
Waveform: square
Pulse width: 1000 µsec
Pulse frequency: 200 Hz, train length of 125 ms, repetition frequency of 4 Hz (25 pulses
per train)
Amplitude: above sensory threshold, highest intensity that could be tolerated without
inducing frank pain
Duration of stimulation per session: 30 minutes
Electrodes: 7 carbon rubber (self-adhesive) Karaya Pads electrodes of 2 x 3 cm
Placement: 10 acupuncture points: GV14, GV4, GB30, GB34, SP13, B1 60, ST36, B1
40, SP9, LI4 and 3 extra tender points
Outcomes Extracted pain outcome: global pain after 13 weeks described as “Pain improvement
(percentage pain improvement based on VAS)”
No function outcome reported
No primary outcome reported
Notes *Investigators named their intervention AL-TENS, but we coded it burst TENS in the
analyses
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No information provided
Allocation concealment? Unclear No information provided
Free of selective reporting? No Quote: “Full details of this (Percent Improvement Pain Scale)
are reported elsewhere”. Investigators however failed to provide
reference.
Adequate blinding of patients? Yes Use of sham device: Codetron, identical in appearance, set at
frequency of 0.2 Hz with a threshold electrical stimulus of 0.5
mA, which caused a sensation on the skin but failed causing the
deep muscle afferent stimulation
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Fargas-Babjak 1989 (Continued)
Incomplete outcome reporting: intention-
to-treat analysis performed?
Pain
No 56 patients randomised but only 19 analysed in the experimen-
tal, and 18 analysed in the control group
Incomplete outcome reporting: intention-
to-treat analysis performed?
Function
Unclear Not applicable
Funding by commercial organisation
avoided?
No Sponsor: Electronic Health Machines
Funding by non-profit organisation? Yes NRC grant no: 689
Garland 2007
Methods Randomised multicentre controlled trial
2-arm parallel group design
Number of participating centres: 3
Trial duration: 12 weeks
Randomisation stratified according to study site
No power calculation reported
Participants 100 patients randomised
58 patients with knee OA reported at baseline; 41 out of 58 candidates for total knee
arthroplasty
Study joints: 58 knees
Number of females: 38 of 58 (66%)
Average age: 66
Disease duration: 8.4 years
Interventions Experimental intervention: pulsed electrical stimulation
Control intervention: sham intervention
Duration of treatment period: 12 weeks
Analgesics allowed and intake assessed, but unclear whether intake was similar.
Device: BIO-1000
Self-administered: yes
Waveform: unclear
Pulse width: unclear
Pulse frequency: 100 Hz
Amplitude: below sensory threshold, initial increase of amplitude up to 12 Volt until a
tingling sensation was felt then reduction of the amplitude until this sensation disap-
peared
Duration of stimulation per session: 8.2 hours in active group, 7.8 hours in sham group
(mean daily application time)
Electrodes: flexible electrodes embedded in garment, type not reported
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Garland 2007 (Continued)
Electrode placement: negative electrode at patella, positive over anterior distal thigh
Outcomes Extracted pain outcome: global pain after 12 weeks, described as “Considering your pain
and symptoms in your study joint how are you doing today? (VAS)”
Extracted function outcome: WOMAC disability subscore after 12 weeks (VAS)
No primary outcome reported
Notes *Due to major protocol violations, all 42 randomised patient of one site were excluded
by Garland et al
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Random number table
Allocation concealment? Yes Central randomisation
Free of selective reporting? Unclear Quote: “Total WOMAC scores were not a defined outcome in
the protocol, but are shown in Tables II(a)-(d).”
Adequate blinding of patients? Yes Use of sham device: BIO-1000, indistinguishable from active
device, with automatic shut-off as soon as amplitude is reduced
(all patients were instructed to reduce intensity just below per-
ception level). Further adjustments required all devices to be
restarted.
Incomplete outcome reporting: intention-
to-treat analysis performed?
Pain
No Due to major protocol violations, all 42 randomised patient of
1 site were excluded by original authors. From the other site, all
patients randomised were included in the analysis.
Incomplete outcome reporting: intention-
to-treat analysis performed?
Function
No See above
Funding by commercial organisation
avoided?
No Sponsor: BioniCare Medical Technologies
Funding by non-profit organisation? Unclear No information provided
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Grimmer 1992
Methods Randomised controlled trial
3-arm parallel group design
Trial duration: 1 day
No power calculation reported
Participants 60 patients randomised
60 patients with knee OA reported at baseline
Study joints: 60 knees
Number of females: 37 of 60 (62%)
Average age: 66 years
Interventions Experimental intervention: high frequency TENS, once only in group 1, burst TENS,
once only in group 2
Control intervention: sham TENS, once only
Duration of treatment period: 1 day
Analgesics not allowed
Device: Medtronic Neuromed Selectra (dual channel)
Self-administered: no
Waveform: unclear
Pulse width: unclear
Pulse frequency: 80 Hz in group 1, 3 Hz trains of 7 80 Hz pulses in group 2
Amplitude: above sensory threshold, strong tolerable tingling paraesthesia
Duration of stimulation per session: 30 minutes
Electrodes: 4 carbon rubber silicone electrodes, 2 x 3 cm
Placement: 4 acupuncture points around the knee: medial (SP9), lateral (GB33), poste-
rior (UB40), anterior (SP10)
Outcomes Extracted pain outcome: global pain immediately after first and only application, de-
scribed as “Immediate pain relief (VAS)”
No function outcome reported
No primary outcome reported
Notes -
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “randomly allocated (by dice) into three groups of 20”
Allocation concealment? Yes By a person independent of the study
Free of selective reporting? Unclear Insufficient information provided; no access to study protocol
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Grimmer 1992 (Continued)
Adequate blinding of patients? Yes Sham device: Medtronic Neuromed Selectra, with non-func-
tioning leads. Patient were told that a very high frequency cur-
rent was being tested and that no skin sensation would be felt.
Incomplete outcome reporting: intention-
to-treat analysis performed?
Pain
Yes Degrees of freedom reported indicate that all randomised pa-
tients were included in the analysis
Incomplete outcome reporting: intention-
to-treat analysis performed?
Function
Unclear Not applicable
Funding by commercial organisation
avoided?
Unclear No information provided
Funding by non-profit organisation? Unclear No information provided
Itoh 2008
Methods Randomised controlled trial
2 x 2 factorial design
Trial duration: 10 weeks
No power calculation reported
Participants 32 patients randomised
32 patients with knee OA reported at baseline
Study joints: 32 knees
Number of females: 21 of 32 (66%)
Interventions Experimental intervention: interferential current stimulation*, once per week
Control intervention: no intervention, optional use of poultice
16 out of 32 patients (50%) allocated to acupuncture using a factorial design; no evidence
for an interaction between treatments
Duration of treatment period: 5 weeks
Analgesics allowed and intake assessed, but unclear whether intake was similar.
Device: HV-F3000 (single channel, 2 pole)
Self-administered: no
Waveform: sinusoidal
Pulse width: not applicable
Pulse frequency: amplitude-modulated frequency of 122 Hz (beat frequency)
Amplitude: above sensory threshold, up to a tingling sensation, 2 to 3 times above sensory
threshold
Duration of stimulation per session: 15 minutes
Placement: site of tenderness and opposite site
Electrodes: 2 disposable electrodes different in size, 809 mm2 and 5688 mm2
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Itoh 2008 (Continued)
Outcomes Extracted pain outcome: global pain after 10 weeks, described as “Pain intensity (VAS)”
Extracted function outcome: WOMAC global scale after 10 weeks (VAS)
Primary outcomes: pain intensity, WOMAC global scale
Notes *The investigators used the label TENS in their report, but from their description of the
intervention it was clear that interferential current stimulation was applied
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer generated block randomisation. Quote “According
to a block randomised allocation table (generated by Sample
Size, version 2.0, Int), the enrolled patients were allocated to (1)
the control (CT) group, (2) the acupuncture (ACP) group, (3)
the transcutaneous electrical nerve stimulation (TENS) group
or (4) the acupuncture and TENS (A&T) group.”
Allocation concealment? Unclear No information provided
Free of selective reporting? Unclear Insufficient information provided, no access to study protocol
Adequate blinding of patients? No No sham intervention
Incomplete outcome reporting: intention-
to-treat analysis performed?
Pain
No 12 out of 16 (75%) randomised to experimental and 12 out of
16 (75%) randomised to control group were analysed
Incomplete outcome reporting: intention-
to-treat analysis performed?
Function
No See above
Funding by commercial organisation
avoided?
Unclear No information provided
Funding by non-profit organisation? Unclear No information provided
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Law 2004
Methods Randomised controlled trial
4-arm parallel group design
Trial duration: 4 weeks
No power calculation reported
Participants 36 patients randomised
36 patients with knee OA reported at baseline
Study joints: 48 knees*
Number of females: 35 of 36 (97%)
Average age: 82 years
Interventions Experimental intervention: 2 Hz TENS in group 1, 100 Hz TENS in group 2, modu-
lation TENS with alternations between 2 to 100 Hz in group 3, 5 times per week in all
groups
Control intervention: sham TENS, 5 times per week
Duration of treatment period: 2 weeks
Unclear whether analgesics were allowed and whether intake was similar between groups
Device: Han Acupoint Nerve Stimulation LH204H
Self-administered: no
Waveform: unclear
Pulse width and frequency: 576 µsec and 2 Hz in group 1, 200 µsec and 100 Hz in
group 2, 576/200 µsec and 2/100 Hz alternation in group 3
Amplitude: above sensory threshold, up to comfortable level, range 25 to 35 mA
Duration of stimulation per session: 40 minutes
Electrodes: 4 rubber electrodes of 4.5 x 3.8 cm
Placement: 4 acupuncture points: ST35, LE4, SP9, GB34
Outcomes Extracted pain outcome: pain on walking after 4 weeks, described as “intensity of pain
felt while walking (VAS)”
No function outcome reported
No primary outcome reported
Notes Outcome data were reported on knee level.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: “Randomization was carried out by drawing lots from
the randomization envelope.”
Allocation concealment? Unclear No information provided
Free of selective reporting? Unclear Insufficient information provided; no access to study protocol
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Law 2004 (Continued)
Adequate blinding of patients? Yes Use of sham device: identical in appearance, internal circuit dis-
connected, no current passed, indicator light on, digital display
of intensity control functioned normally. Quote: “Only thera-
pists who administered treatment to the subjects knew the group
allocation, while the subjects and the assessor were not given this
information.”
Incomplete outcome reporting: intention-
to-treat analysis performed?
Pain
No In total, 3 patients dropped out and were excluded from anal-
ysis, as indicated by Gladys Cheing and Pearl Law in personal
communication
Incomplete outcome reporting: intention-
to-treat analysis performed?
Function
Unclear Not applicable
Funding by commercial organisation
avoided?
Unclear No information provided
Funding by non-profit organisation? Unclear No information provided
Law 2004a
Methods Randomised controlled trial
2-arm parallel group design
Trial duration: 2 weeks
Unstratified randomisation
Multicentre trial with 2 centres
No power calculation reported
Participants 39 patients randomised
39 patients with knee OA reported at baseline
Study joints: 39 knees
Number of females: 37 of 39 (95%)
Average age: 75 years
Average BMI: 27 kg/m2
Average disease duration: 7.6 years
Interventions Experimental intervention: TENS, 5 times per week
Control intervention: sham TENS, 5 times per week
Duration of treatment period: 2 weeks
Unclear whether analgesics were allowed and whether intake was similar between groups
Device: ITO model 120Z (dual channel)
Self-administered: no
Waveform: unclear
Pulse width: 200 µsec
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Law 2004a (Continued)
Pulse frequency: 100 Hz
Amplitude: above sensory threshold, up to a comfortable level, range 25-35 mA
Duration of stimulation per session: 40 minutes
Electrodes: 4 rubber electrodes, 4.5 x 3.8 cm2
Placement: acupuncture points: ST35, LE4, SP9, GB34
Outcomes Extracted pain outcome: pain on walking after 2 weeks, described as “intensity of pain
felt while walking (VAS)”**
Extracted function outcome: walking disability after 2 weeks, described as “Timed-Up-
and-Go test over 3 meters (seconds)”
No primary outcome reported
Notes **Only baseline values reported in the report. Contact established with investigators Law
and Cheing, who provided end of treatment and follow-up data.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: “’by drawing lots from the randomization envelope with-
out replacement”
Allocation concealment? Unclear Quote : “(...) carried out by physiotherapists who performed the
treatment”
Free of selective reporting? No No results reported for some outcomes mentioned in the meth-
ods section, including pain intensity on VAS
Adequate blinding of patients? Yes Use of sham device: ITO model 120Z, no current delivered but
flashing light on. Quote: “The assessors and subjects were blind
to the group allocation. All subjects were told that when the
indicator light of the TENS was blinking, it meant the machine
was working properly. Theymight or might not feel any tingling
sensation during treatment because the intensity of the current
was small.”
Incomplete outcome reporting: intention-
to-treat analysis performed?
Pain
No In total, 3 patients dropped out and were excluded from anal-
ysis, as indicated by Gladys Cheing and Pearl Law in personal
communication
Incomplete outcome reporting: intention-
to-treat analysis performed?
Function
No See above
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Law 2004a (Continued)
Funding by commercial organisation
avoided?
Unclear No information provided
Funding by non-profit organisation? Unclear No information provided
Ng 2003
Methods Randomised controlled trial
3-arm parallel group design
Trial duration: 4 weeks
Unstratified randomisation
No power calculation reported
Participants 24 patients randomised
24 patients with knee OA reported at baseline
Study joints: 24 knees
Number of females: 23 of 24 (96%)
Average age: 85 years
Interventions Experimental intervention: TENS, 4 times per week, with a total of 8 applications and
educational pamphlet
Control intervention: educational pamphlet
Duration of treatment period: 2 weeks
Unclear whether analgesics were allowed and whether intake was similar between groups
Device: ITO model F-2 (dual channel)
Self-administered: no
Waveform: unclear
Pulse width: 200 µsec
Pulse frequency: 2 Hz
Amplitude: above sensory threshold, until strong, tolerable, stroking sensation, preferably
evoking phasic muscle contraction
Duration of stimulation per session: 20 minutes
Electrode placement: acupuncture points ST35, EX-LE-4
Electrodes: 50 x 35 mm2
Outcomes Extracted pain outcome: global pain after 4 weeks, described as “pain (Numeric rating
scale (NRS))”
No function outcome reported
No primary outcome reported
Notes 2 out of 3 trial arms qualified for inclusion in this review
Risk of bias
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Ng 2003 (Continued)
Item Authors’ judgement Description
Adequate sequence generation? Yes Drawing lots. Quote: “Subjects were randomly assigned by
drawing a piece of paper that designated each person to the EA,
TENS, and control groups”
Allocation concealment? Unclear No information provided
Free of selective reporting? Yes Quote: “In each evaluation session, three outcomemeasureswere
collected.” The authors present results of all these 3 outcomes.
Adequate blinding of patients? No No sham intervention
Incomplete outcome reporting: intention-
to-treat analysis performed?
Pain
Unclear No information provided
Incomplete outcome reporting: intention-
to-treat analysis performed?
Function
Unclear Not applicable
Funding by commercial organisation
avoided?
Unclear No information provided
Funding by non-profit organisation? Unclear No information provided
Quirk 1985
Methods Randomised controlled trial
3-arm parallel group design*
Trial duration: 26 weeks
No power calculation reported
Participants 38 patients randomised
38 patients with knee OA reported at baseline
Study joints: 38 knees
Number of females: 29 of 38 (76%)
Average age: 63 years
Interventions Experimental intervention: interferential current + exercise, interferential current stim-
ulation: 3 times per week, exercise twice daily
Control intervention: exercise twice daily
Duration of treatment period: 4 weeks
Analgesics allowed, unclear whether intake was similar between groups
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Quirk 1985 (Continued)
Device: Endomed 433 and Vacutron 423 (unclear whether 2 or 4 pole)
Self-administered: no
Waveform: interferential
Pulse width: not applicable
Pulse frequency: 0 to 100 Hz 10 minutes, 130 Hz last 5 minutes
Amplitude: not reported
Duration of stimulation per session: 15 minutes
Electrodes: suction electrodes
Placement: not reported
Outcomes Extracted pain outcome: other after 26 weeks, described as “Pain composite score with
items rest, post-exercise and night pain (approach unclear; either VAS or verbal scoring
technique modified after Newland)”**
Extracted function outcome: other algofunctional scale after 26 weeks, described as
“Overall clinical condition scale developed by authors, which was based on 3 items for
pain; rest-, post-exercise-, night pain and 3 for function; gait, method of climbing stairs
and using walking aids (most likely Likert)”.
No primary outcome reported
Notes *1 trial arm, in which shortwave diathermy was given, was excluded, **only baseline
values with standard error and P values for change from baseline per group reported. No
contact could be established with the investigators.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No information provided
Allocation concealment? Unclear No information provided
Free of selective reporting? No No results reported for some outcomes mentioned in the meth-
ods section, including maximum knee girth
Adequate blinding of patients? No No sham intervention
Incomplete outcome reporting: intention-
to-treat analysis performed?
Pain
Yes Quote: “All patients completed their therapy and the first two
assessments (baseline and end of treatment), while 92% com-
pleted the final assessment (3-6 months after treatment)”
Incomplete outcome reporting: intention-
to-treat analysis performed?
Function
Yes See above
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Quirk 1985 (Continued)
Funding by commercial organisation
avoided?
Unclear No information provided
Funding by non-profit organisation? Unclear No information provided
Smith 1983
Methods Randomised sham controlled trial
2-arm parallel group design
Trial duration: 8 weeks
Randomisation stratified according to gender
Multicentre trial with 2 centres
No power calculation reported
Participants 32 patients randomised
30 patients with knee OA reported at baseline
Study joints: 30 knees
Number of females: 20 of 30 (67%)
Average age: 68 years
Interventions Experimental intervention: TENS, twice per week*
Control intervention: sham TENS, twice per week*
Duration of treatment period: 4 weeks
Analgesics intake assessed and found to be similar between groups
Device: RDG Tiger Pulse
Self-administered: no
Waveform: square
Pulse width: 80 µsec
Pulse frequency: 32 to 50 Hz
Amplitude: above sensory threshold, adjusted up to a comfortable tingling sensation
Duration of stimulation per session: 20 minutes
Electrodes: 4 Lec Tec pads applied with electrode jelly
Placement: tender knee points or acupuncture points (SP9, xiyan and UB40)
Outcomes Extracted pain outcome: global pain after 8 weeks, described as “Weekly pain score
derived from daily pain recording (linear 7-point scale)”**
No function outcome reported
No primary outcome reported
Notes *Preceded by 1 ’standard’ week without any treatment, **No pain outcome data pre-
sented, investigators were contacted, but we did not receive any reply. This study only
contributed in safety analysis.
Risk of bias
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Smith 1983 (Continued)
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer generated. Quote: “(...) assigned by random com-
puter programme and effected by using sealed envelopes con-
taining cards which defined the treatment (...)”.
Allocation concealment? Unclear Sealed assignment envelopes, but unclear whether these were
opaque and sequential
Free of selective reporting? No No results reported for some outcomes mentioned in the meth-
ods section, including sleep disturbance
Adequate blinding of patients? Yes Use of sham device: RDG Tiger Pulse with broken electrode
connection at jack point, no current passed but flashing light
on. Quote: “Exactly the same procedure were followed for both
the treatment and control groups”.
Incomplete outcome reporting: intention-
to-treat analysis performed?
Pain
No 15 out of 16 (0.94) randomised to experimental and 15 out of
16 (0.94) randomised to control group were analysed
Incomplete outcome reporting: intention-
to-treat analysis performed?
Function
Unclear Not applicable
Funding by commercial organisation
avoided?
Unclear No information provided
Funding by non-profit organisation? Unclear No information provided
Yurtkuran 1999
Methods Randomised controlled trial
4-arm parallel group design
Trial duration: 2 weeks
No power calculation reported
Participants 100 patients randomised, 25 per group
100 patients with knee OA reported at baseline
Study joints: 100 knees
Number of females: 91 of 100 (91%)
Average age: 58 years
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Yurtkuran 1999 (Continued)
Interventions Experimental intervention: TENS, 5 times per week
Control intervention: sham TENS, 5 times per week
Duration of treatment period: 2 weeks
Unclear whether analgesics were allowed and whether intake was similar between groups
Device: MEA-TENS (dual channel)
Self-administered: no
Waveform: rectangular
Pulse width: 1000 µsec
Pulse frequency: 4 Hz*
Amplitude: above sensory threshold, up to muscle contraction, just below pain tolerance
threshold
Duration of stimulation per session: 20 minutes
Electrodes: 4 small MEA rubber electrodes
Placement: 4 acupuncture points SP-9, GB-34, ST-34, ST-35
Outcomes Extracted pain outcome: global pain after 2 weeks described as “Overall present pain
intensity at rest (Likert)”
Extracted function outcome: walking disability after 2 weeks, described as “50 foot
walking time (in minutes)”
No primary outcome reported
Notes Two out of 4 groups, the electroacupuncture and ice massage groups, were excluded
in this review. *Investigators named their intervention AL-TENS, but we coded it low
frequency TENS in our analysis.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No information provided
Allocation concealment? Unclear No information provided
Free of selective reporting? Unclear Trial protocol not accessible, methods section not explicit about
pre-specified outcomes
Adequate blinding of patients? Yes Sham device: MEA-TENS with broken lead at jack plug, no
current passed but red indicator light on. Quote: “(...) treatment
appeared to be done in the same way as the other groups without
the subjects suspecting the nature of the stimulation”.
Incomplete outcome reporting: intention-
to-treat analysis performed?
Pain
No Investigators reported that “no subject was withdrawn either ac-
tive or placebo groups”. However, the reported degrees of free-
dom indicate that 5 out of 100 patients were not included. It
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Yurtkuran 1999 (Continued)
remained unclear to which of the 4 groups the excluded patients
belonged.
Incomplete outcome reporting: intention-
to-treat analysis performed?
Function
No See above
Funding by commercial organisation
avoided?
Unclear No information provided
Funding by non-profit organisation? Unclear No information provided
Zizic 1995
Methods Randomised controlled trial
2-arm parallel group design
Trial duration: 34 weeks
Multicentre trial with 5 centres
No power calculation reported
Participants 78 patients randomised
71 patients with knee OA reported at baseline
Study joints: 71 knees
Number of females: 33 of 71 (46%)
Interventions Experimental intervention: pulsed electrostimulation stimulation, daily application
Control intervention: sham pulsed electrostimulation, daily application
Duration of treatment period: 4 weeks
Analgesics allowed, intake assessed and found to be similar between groups.
Device: Bionicare Stimulator BIO-1000
Self-administered: yes
Waveform: monophasic, spiked
Pulse width: unclear
Pulse frequency: 100 Hz
Amplitude: below sensory threshold, initial increase of amplitude until a tingling sensa-
tion was felt then reduction of the amplitude until this sensation disappeared
Duration of stimulation: 6 to 10 hours per day
Electrodes: 2, unclear whether positioned in knee garment
Placement: one on knee, other on thigh directly above that knee
Outcomes Extracted pain outcome: global pain after 34 weeks described as “Patient evaluation of
pain of treated knee (Baseline based on 0-10 VAS, follow-up based on % change from
baseline)”
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Zizic 1995 (Continued)
Extracted function outcome: patient’s global assessment after 34 weeks, described as
“Patient evaluation of function of treated knee (Baseline based on 0-10 VAS, follow-up
based on % change from baseline)”
More than 2 primary outcomes reported (1 physician global evaluation; 2) VAS pain; 3)
VAS function)
Notes -
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No information provided
Allocation concealment? Unclear No information provided
Free of selective reporting? No No results reported for some outcomes mentioned in the meth-
ods, including walking time, tenderness and swelling
Adequate blinding of patients? Yes Shamdevice: BIO-1000, identical in appearance to active device,
with automatic shut-off as soon as amplitude is reduced (all
patientswere instructed to reduce intensity just belowperception
level)
Incomplete outcome reporting: intention-
to-treat analysis performed?
Pain
No 38 out of 41 (0.93) randomised to experimental and 33 out of
37 (0.89) randomised to control group were analysed
Incomplete outcome reporting: intention-
to-treat analysis performed?
Function
No See above
Funding by commercial organisation
avoided?
No Sponsor: Murray Electronics
Funding by non-profit organisation? Unclear No information provided
BMI = body mass index
min = minutes
OA = osteoarthritis
VAS = visual analogue scale
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Characteristics of excluded studies [ordered by study ID]
Barr 2004 Less than 50% of patients diagnosed with osteoarthritis of the knee
Bernau 1981 Not a randomised controlled trial, use of active control groups. Additional description: comparing diadynamic
electrostimulation df, diadynamic electrostimulation cf and galvanic current
Burch 2008 Use of active control group. Additional description: randomised controlled trial comparing interferential
current stimulation followed by patterned muscle stimulation and low-current transcutaneous electrical nerve
stimulation (TENS).
Cauthen 1975 Not concerning osteoarthritis
Commandre 1977 No randomised controlled trial (review)
Cottingham 1985a Not transcutaneous but subcutaneous application
Cottingham 1985b Not transcutaneous but subcutaneous application. Abstract referring to sameRCTas described inCottingham
1985a.
Durmus 2005 Use of active control group (exercise)
Gaines 2001 Neuromuscular electrostimulation primarily aiming at muscle strengthening
Gaines 2004 Neuromuscular electrostimulation primarily aiming at muscle strengthening
Gibson 1989 Most likely not a randomised controlled trial; percutaneous electrostimulation primarily aiming at muscle
strengthening
Godfrey 1979 Faradic electrostimulation with parameters set to increase muscle strength and use of active control (exercise
plus low intensity (sham) faradic electrostimulation)
Grigor’eva 1992 No relevant pain or function outcomes
Guven 2003 High voltage galvanic electrostimulation for muscle strengthening
Hamilton 1959 Only 34% of patients sufferedOA; use of active controls. Additional description: cross-over design evaluating
faradic electrostimulation.
Huang 2000 TENS as part of a combined experimental intervention. Additional description design: 3 groups, Group A
receiving auricular acupuncture, diet control and aerobic exercise, Group B like A with addition of TENS
and ultrasound, Group C receiving TENS and ultrasound; unclear whether allocation was at random.
Jensen 1991 Use of active control: high frequency TENS versus low frequency TENS
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Kang 2007 Percutaneous electrostimulation
Katsnelson 2004 Electrode placement not involving knee innervation: transcranial electrostimulation
Komarova 1998 Electrode placement not involving knee innervation: transcranial electrostimulation
Lewis 1984 Cross-over RCT reporting pooled results after completion of all phases. Contact established with Daniel and
Beverly Lewis, who were unable to provide results for the first phase (before cross-over)
Lewis 1985 RCT reporting P values of effect only. Contact established with Daniel and Beverly Lewis, who could not
provide any additional outcome data, nor could they indicate whether the design concerned a cross-over or
a parallel RCT
Lewis 1988 Published abstract addressing the same cross-over RCT reported by Lewis 1994
Lewis 1994 Cross-over RCT reporting pooled results after completion of all phases. Contact established with Daniel and
Beverly Lewis, who were unable to provide results for the first phase (before cross-over)
Lone 2003 Not a randomised controlled study. Additional description: before-after study design that was incorrectly
labelled as randomised study by original authors.
Lund 2005 Not concerning osteoarthritis
Macchione 1995 Not a randomised controlled trial (review)
Matti 1987 Not concerning osteoarthritis, not a randomised clinical trial. Tetanus-like faradisation electrostimulation
with exercise after surgical removal of meniscus, primarily aiming at muscle enhancement. Active control
with 10 Hz sinusoidal current application and exercise.
Miranda-Filloy 2005 Electrical muscle stimulation using sport400 (Complex), primarily aiming at muscle strengthening
Mont 2006 Not a randomised clinical trial. Description: comparative study with historical control evaluating pulsed
electrostimulation.
Oldham 1995 Neuromuscular electrostimulation primarily aiming at muscle strengthening
Oldham 1997 Electrostimulation primarily aiming at muscle strengthening
Oosterhof 2008 Mixed population, only 4 out of 163 patients reported to have knee, hip or ankle OA
Paillard 2005 Not concerning osteoarthritis (healthy volunteers)
Picaza 1975 Not concerning osteoarthritis and not a randomised controlled trial
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Salaj 2001 Not a randomised controlled trial, combined multiple interventions in both interventions and control group
Salim 1996 Not a randomised controlled trial (review)
Sluka 1998 Animal study
Sok 2007 Concerns chronic knee pain. First author was contacted by email to verify howmany patients had osteoarthri-
tis. No response received. Additional description: article in Korean, using a TENS device, abstract however
suggests that parameters were set to strengthen muscles.
Svarcova 1988a Use of active control groups. Additional description: controlled trial with groups receiving either galvanic
electrostimulation or YES ultrasound or pulsed shortwaves. Within these groups, half of the patients received
ibuprofen, half received placebo ibuprofen. It was unclear whether allocation was at random.
Svarcova 1988b See Svarcova 1988a.Double publication of the same study, including the same number of patient and outcome
data.
Svarcova 1990 Use of active control group. Additional description: galvanic electrostimulation versus electroacupuncture.
Talbot 2003 Neuromuscular electrostimulation primarily aiming at muscle strengthening
Tam 2004 No relevant pain or function outcomes used
Taylor 1981 Incomplete presentation of data. Additional description: cross-over randomised clinical trial presenting pooled
results only. Contact established with Mark Hallett, who was unable to provide data concerning the first
phase, before cross-over. We were unable to contact the other authors.
Tulgar 1991 Not concerning osteoarthritis
Volklein 1990 Use of active control group. Additional description: random allocation of patients to 4 different types of
diadynamic current.
Weiner 2007 Not transcutaneous but periosteal (needle) application
Zivkovic 2005 Use of active control group. Additional description: the combination of low-energy laser, pulsed electromag-
netic field and kinesitherapy was compared to the combination of electrotherapy, pulsed electromagnetic field
and kinesitherapy.
OA = osteoarthritis
RCT = randomised controlled trial
TENS = transcutaneous electrical nerve stimulation
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Characteristics of ongoing studies [ordered by study ID]
Fary 2008
Trial name or title ACTRNI2607000492459
Methods Double-blind, randomised placebo-controlled trial
Randomisation method: computer-generated block randomisation with stratification for gender, age and
intensity of pain
Concealment of allocation: by independent administrator
Blinding: patients, those administering treatment/s, those assessing outcomes, those analysing results/data
Sample size calculation: reported
Analyses based on intention-to-treat principle
Trial duration: 26 weeks
Sponsored by: non-profit organisation Arthritis Australia and Physiotherapy Research Foundation
Participants 70 patients with primary knee OA to be randomised
Study joints: 70 knees
Selection criteria: persistent, stable pain for minimum of 3 months, at least 25 mm on a 100 mm VAS
Interventions Experimental intervention: pulsed electrostimulation, daily
Control intervention: sham pulsed electrostimulation, daily
Duration of treatment period: 26 weeks
Analgesics allowed and measured with diary
Device: Metron Digi-10s, adapted by engineer
Self-administered: yes
Waveform: pulsed, exponentially declining
Pulse width: not reported
Pulse frequency: 100 Hz
Amplitude: below sensory threshold
Duration of stimulation: minimally 7 hours per day
Electrodes: not reported
Electrode placement: not reported
Sham device: identical in appearance
Outcomes Primary outcomes: conflicting information reported in Australian/New Zealand clinical trial register
(ANZCTR) and subsequent publication in BMC. In ANZCR reported as pain on VAS, in BMC more than
2 primary outcomes are reported; pain (VAS and WOMAC), function (WOMAC), and patient global as-
sessment (VAS). Main time points of interest are reported consistently as baseline, 4, 16 and 26 weeks.
Secondary outcomes: in ANZCTR reported as function (WOMAC) and patient global assessment (VAS);
in BMC reported as stiffness (WOMAC 3.1), quality of life (SF-36), global perceived effect scale (GPES),
physical activity (Human Activity Profile (HAP) questionnaire plus accelerometers
Safety outcomes: in BMC, the recording of adverse events was reported
Starting date 26th of September 2007
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Fary 2008 (Continued)
Contact information Robyn E Fary
Curtin University of Technology, School of Physiotherapy,
Kent Street, Bentley, WA, 6102, Australia
Tel: 08 9266 3667
Email: R.Fary@curtin.edu.au
Notes Status at 17 July 2009: open to recruitment
Palmer 2007
Trial name or title ISRCTN12912789
Methods A randomised, sham-controlled trial with 3 parallel arms
Randomisation method: not reported
Concealment of allocation: not reported
Blinding: not reported
Sample size calculation: not reported
Analyses: not reported whether is based on intention-to-treat principle
Trial duration: 6 weeks
Sponsored by: not reported
Participants 261 (87 in each arm) patients with primary knee OA to be randomised
Study joints: knees
Selection criteria: knee pain, radiographic (X-ray) evidence of osteophytes, and at least 1 of the following 3
criteria: 50 years or older, morning stiffness that lasts for less than 30 minutes, crepitus on active movement
Interventions Experimental intervention: TENS, asmuch as needed and group education including self-efficacy and exercise
training, once per week
Control intervention 1: Sham TENS, as much as needed and group education once per week, as described
above
Control intervention 2: group education once per week, as described above
Duration of treatment period: 6 weeks
Analgesics: unclear wether analgesic intake is allowed and is measured
Device: not reported
Self-administered: yes
Waveform: not reported
Pulse width: not reported
Pulse frequency: not reported
Amplitude: “strong but comfortable” tingling sensation
Duration of stimulation: defined as “as much as needed”
Electrodes: not reported
Electrode placement: within or close to the site of pain
Sham device: identical in appearance, displays are active but there is no current output
67Transcutaneous electrostimulation for osteoarthritis of the knee (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Palmer 2007 (Continued)
Outcomes Primary outcome: WOMAC function subscale (at baseline, 3, 6, 12 and 24 weeks)
Secondary outcomes:
1. Total WOMAC score and WOMAC pain and stiffness subscale scores (at baseline, 3, 6, 12 and 24 weeks)
2. Knee extensor torque (quadriceps strength) (at baseline, 3, 6, 12 and 24 weeks)
3. Patient global assessment of change (at 3, 6, 12 and 24 weeks)
4. Self-efficacy for exercise (at baseline and 24 weeks)
5. Self-reported exercise adherence (at baseline, 3, 6, 12 and 24 weeks)
6. Logged TENS usage time (at 6 weeks)
Starting date 1 October 2007
Contact information Dr Shea Palmer
Faculty of Health and Social Care
University of the West of England
Blackberry Hill
Bristol
BS16 1DD
United Kingdom
Tel +44 (0)117 328 8919
Email Shea.Palmer@uwe.ac.uk
Notes Status at 17 July 2009: completed at 30 June 2009
OA = osteoarthritis
TENS = transcutaneous electrical nerve stimulation
VAS = visual analogue scale
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D A T A A N D A N A L Y S E S
Comparison 1. Any type of transcutaneous electrostimulation versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain 16 726 Std. Mean Difference (Random, 95% CI) -0.86 [-1.23, -0.49]
1.1 TENS 11 465 Std. Mean Difference (Random, 95% CI) -0.85 [-1.36, -0.34]
1.2 Interferential current
stimulation
4 132 Std. Mean Difference (Random, 95% CI) -1.20 [-1.99, -0.42]
1.3 Pulsed electrostimulation 2 129 Std. Mean Difference (Random, 95% CI) -0.41 [-0.77, -0.05]
2 Number of patients withdrawn
or dropped out because of
adverse events
8 363 Risk Ratio (IV, Random, 95% CI) 0.97 [0.16, 6.00]
2.1 TENS 6 255 Risk Ratio (IV, Random, 95% CI) 0.60 [0.03, 14.15]
2.2 Interferential current
stimulation
1 30 Risk Ratio (IV, Random, 95% CI) Not estimable
2.3 Pulsed electrostimulation 1 78 Risk Ratio (IV, Random, 95% CI) 1.80 [0.17, 19.10]
3 Function 9 407 Std. Mean Difference (Random, 95% CI) -0.34 [-0.54, -0.14]
3.1 TENS 5 204 Std. Mean Difference (Random, 95% CI) -0.33 [-0.69, 0.03]
3.2 Interferential current
stimulation
3 74 Std. Mean Difference (Random, 95% CI) -0.27 [-0.75, 0.20]
3.3 Pulsed electrostimulation 2 129 Std. Mean Difference (Random, 95% CI) -0.36 [-0.72, -0.00]
4 Number of patients experiencing
any adverse event
3 175 Risk Ratio (IV, Random, 95% CI) 1.02 [0.53, 1.97]
4.1 TENS 1 39 Risk Ratio (IV, Random, 95% CI) Not estimable
4.2 Pulsed electrostimulation 2 136 Risk Ratio (IV, Random, 95% CI) 1.02 [0.53, 1.97]
5 Number of patients experiencing
any serious adverse event
4 195 Risk Ratio (IV, Random, 95% CI) 0.33 [0.02, 7.32]
5.1 TENS 2 59 Risk Ratio (IV, Random, 95% CI) 0.33 [0.02, 7.32]
5.2 Pulsed electrostimulation 2 136 Risk Ratio (IV, Random, 95% CI) Not estimable
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Analysis 1.1. Comparison 1 Any type of transcutaneous electrostimulation versus control, Outcome 1 Pain.
Review: Transcutaneous electrostimulation for osteoarthritis of the knee
Comparison: 1 Any type of transcutaneous electrostimulation versus control
Outcome: 1 Pain
Study or subgroup Experimental Control Std. Mean Difference (SE) Std. Mean Difference Weight Std. Mean Difference
N N IV,Random,95% CI IV,Random,95% CI
1 TENS
Adedoyin 2005 15 7 0.6 (0.46) 5.1 % 0.60 [ -0.30, 1.50 ]
Bal 2007 28 28 -0.25 (0.27) 6.3 % -0.25 [ -0.78, 0.28 ]
Cetin 2008 20 20 0.02 (0.32) 6.0 % 0.02 [ -0.61, 0.65 ]
Cheing 2002 15 15 -0.13 (0.37) 5.7 % -0.13 [ -0.86, 0.60 ]
Cheing 2002 16 16 -0.23 (0.35) 5.8 % -0.23 [ -0.92, 0.46 ]
Cheing 2003 30 8 -3.28 (0.55) 4.5 % -3.28 [ -4.36, -2.20 ]
Fargas-Babjak 1989 19 18 -0.87 (0.34) 5.9 % -0.87 [ -1.54, -0.20 ]
Grimmer 1992 40 20 -0.65 (0.28) 6.2 % -0.65 [ -1.20, -0.10 ]
Law 2004 38 10 -1.79 (0.46) 5.1 % -1.79 [ -2.69, -0.89 ]
Law 2004a 21 15 -2.57 (0.46) 5.1 % -2.57 [ -3.47, -1.67 ]
Ng 2003 8 8 -1.1 (0.54) 4.5 % -1.10 [ -2.16, -0.04 ]
Yurtkuran 1999 25 25 -0.66 (0.29) 6.2 % -0.66 [ -1.23, -0.09 ]
Subtotal (95% CI) 66.2 % -0.85 [ -1.36, -0.34 ]
Heterogeneity: Tau2 = 0.64; Chi2 = 64.90, df = 11 (P<0.00001); I2 =83%
Test for overall effect: Z = 3.30 (P = 0.00098)
2 Interferential current stimulation
Adedoyin 2002 15 15 -1.58 (0.42) 5.3 % -1.58 [ -2.40, -0.76 ]
Adedoyin 2005 16 8 -0.12 (0.44) 5.2 % -0.12 [ -0.98, 0.74 ]
Defrin 2005 45 9 -1.99 (0.41) 5.4 % -1.99 [ -2.79, -1.19 ]
Itoh 2008 12 12 -1.08 (0.44) 5.2 % -1.08 [ -1.94, -0.22 ]
Subtotal (95% CI) 21.1 % -1.20 [ -1.99, -0.42 ]
Heterogeneity: Tau2 = 0.46; Chi2 = 10.61, df = 3 (P = 0.01); I2 =72%
Test for overall effect: Z = 2.99 (P = 0.0028)
3 Pulsed electrostimulation
Garland 2007 39 19 -0.38 (0.28) 6.2 % -0.38 [ -0.93, 0.17 ]
Zizic 1995 38 33 -0.43 (0.24) 6.5 % -0.43 [ -0.90, 0.04 ]
Subtotal (95% CI) 12.7 % -0.41 [ -0.77, -0.05 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
-4 -2 0 2 4
Favours experimental Favours control
(Continued . . . )
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Study or subgroup Experimental Control Std. Mean Difference (SE) Std. Mean Difference Weight Std. Mean Difference
N N IV,Random,95% CI IV,Random,95% CI
Test for overall effect: Z = 2.24 (P = 0.025)
Total (95% CI) 100.0 % -0.86 [ -1.23, -0.49 ]
Heterogeneity: Tau2 = 0.50; Chi2 = 84.34, df = 17 (P<0.00001); I2 =80%
Test for overall effect: Z = 4.54 (P < 0.00001)
-4 -2 0 2 4
Favours experimental Favours control
Analysis 1.2. Comparison 1 Any type of transcutaneous electrostimulation versus control, Outcome 2
Number of patients withdrawn or dropped out because of adverse events.
Review: Transcutaneous electrostimulation for osteoarthritis of the knee
Comparison: 1 Any type of transcutaneous electrostimulation versus control
Outcome: 2 Number of patients withdrawn or dropped out because of adverse events
Study or subgroup Experimental Control Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 TENS
Cheing 2002 0/16 0/18 0.0 [ 0.0, 0.0 ]
Cheing 2003 0/30 1/10 0.12 [ 0.01, 2.69 ]
Grimmer 1992 0/40 0/20 0.0 [ 0.0, 0.0 ]
Law 2004a 0/22 0/17 0.0 [ 0.0, 0.0 ]
Smith 1983 1/16 0/16 3.00 [ 0.13, 68.57 ]
Yurtkuran 1999 0/25 0/25 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 149 106 0.60 [ 0.03, 14.15 ]
Total events: 1 (Experimental), 1 (Control)
Heterogeneity: Tau2 = 2.68; Chi2 = 2.05, df = 1 (P = 0.15); I2 =51%
Test for overall effect: Z = 0.32 (P = 0.75)
2 Interferential current stimulation
Adedoyin 2002 0/15 0/15 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 15 15 0.0 [ 0.0, 0.0 ]
Total events: 0 (Experimental), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
3 Pulsed electrostimulation
0.01 0.1 1 10 100
Favours experimental Favours control
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Study or subgroup Experimental Control Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Zizic 1995 2/41 1/37 1.80 [ 0.17, 19.10 ]
Subtotal (95% CI) 41 37 1.80 [ 0.17, 19.10 ]
Total events: 2 (Experimental), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
Total (95% CI) 205 158 0.97 [ 0.16, 6.00 ]
Total events: 3 (Experimental), 2 (Control)
Heterogeneity: Tau2 = 0.54; Chi2 = 2.51, df = 2 (P = 0.29); I2 =20%
Test for overall effect: Z = 0.04 (P = 0.97)
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 1.3. Comparison 1 Any type of transcutaneous electrostimulation versus control, Outcome 3
Function.
Review: Transcutaneous electrostimulation for osteoarthritis of the knee
Comparison: 1 Any type of transcutaneous electrostimulation versus control
Outcome: 3 Function
Study or subgroup Experimental Control Std. Mean Difference (SE) Std. Mean Difference Weight Std. Mean Difference
N N IV,Random,95% CI IV,Random,95% CI
1 TENS
Adedoyin 2005 15 7 0 (0.45) 5.2 % 0.0 [ -0.88, 0.88 ]
Bal 2007 28 28 -0.43 (0.27) 14.4 % -0.43 [ -0.96, 0.10 ]
Cetin 2008 20 20 0.15 (0.32) 10.2 % 0.15 [ -0.48, 0.78 ]
Law 2004a 21 15 -0.28 (0.34) 9.1 % -0.28 [ -0.95, 0.39 ]
Yurtkuran 1999 25 25 -0.88 (0.3) 11.6 % -0.88 [ -1.47, -0.29 ]
Subtotal (95% CI) 50.5 % -0.33 [ -0.69, 0.03 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 6.30, df = 4 (P = 0.18); I2 =36%
Test for overall effect: Z = 1.78 (P = 0.075)
2 Interferential current stimulation
Adedoyin 2005 16 8 -0.36 (0.45) 5.2 % -0.36 [ -1.24, 0.52 ]
Itoh 2008 12 12 -0.56 (0.42) 5.9 % -0.56 [ -1.38, 0.26 ]
Quirk 1985 12 14 0.04 (0.39) 6.9 % 0.04 [ -0.72, 0.80 ]
-4 -2 0 2 4
Favours experimental Favours control
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Study or subgroup Experimental Control Std. Mean Difference (SE) Std. Mean Difference Weight Std. Mean Difference
N N IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 18.0 % -0.27 [ -0.75, 0.20 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.15, df = 2 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 1.13 (P = 0.26)
3 Pulsed electrostimulation
Garland 2007 39 19 -0.29 (0.28) 13.4 % -0.29 [ -0.84, 0.26 ]
Zizic 1995 38 33 -0.41 (0.24) 18.2 % -0.41 [ -0.88, 0.06 ]
Subtotal (95% CI) 31.5 % -0.36 [ -0.72, 0.00 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 1.97 (P = 0.049)
Total (95% CI) 100.0 % -0.34 [ -0.54, -0.14 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 7.64, df = 9 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 3.29 (P = 0.0010)
-4 -2 0 2 4
Favours experimental Favours control
Analysis 1.4. Comparison 1 Any type of transcutaneous electrostimulation versus control, Outcome 4
Number of patients experiencing any adverse event.
Review: Transcutaneous electrostimulation for osteoarthritis of the knee
Comparison: 1 Any type of transcutaneous electrostimulation versus control
Outcome: 4 Number of patients experiencing any adverse event
Study or subgroup Experimental Control Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 TENS
Law 2004a 0/22 0/17 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 22 17 0.0 [ 0.0, 0.0 ]
Total events: 0 (Experimental), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
2 Pulsed electrostimulation
Garland 2007 7/39 4/19 0.85 [ 0.28, 2.56 ]
Zizic 1995 10/41 8/37 1.13 [ 0.50, 2.55 ]
Subtotal (95% CI) 80 56 1.02 [ 0.53, 1.97 ]
Total events: 17 (Experimental), 12 (Control)
0.01 0.1 1 10 100
Favours experimental Favours control
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Study or subgroup Experimental Control Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Heterogeneity: Tau2 = 0.0; Chi2 = 0.16, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.06 (P = 0.95)
Total (95% CI) 102 73 1.02 [ 0.53, 1.97 ]
Total events: 17 (Experimental), 12 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.16, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.06 (P = 0.95)
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Analysis 1.5. Comparison 1 Any type of transcutaneous electrostimulation versus control, Outcome 5
Number of patients experiencing any serious adverse event.
Review: Transcutaneous electrostimulation for osteoarthritis of the knee
Comparison: 1 Any type of transcutaneous electrostimulation versus control
Outcome: 5 Number of patients experiencing any serious adverse event
Study or subgroup Experimental Control Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 TENS
Cheing 2003 0/10 1/10 0.33 [ 0.02, 7.32 ]
Law 2004a 0/22 0/17 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 32 27 0.33 [ 0.02, 7.32 ]
Total events: 0 (Experimental), 1 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.70 (P = 0.49)
2 Pulsed electrostimulation
Garland 2007 0/41 0/37 0.0 [ 0.0, 0.0 ]
Zizic 1995 0/39 0/19 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 80 56 0.0 [ 0.0, 0.0 ]
Total events: 0 (Experimental), 0 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 0 (P<0.00001); I2 =0.0%
Test for overall effect: Z = 0.0 (P < 0.00001)
Total (95% CI) 112 83 0.33 [ 0.02, 7.32 ]
Total events: 0 (Experimental), 1 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.70 (P = 0.49)
0.01 0.1 1 10 100
Favours experimental Favours control
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A P P E N D I C E S
Appendix 1. MEDLINE, EMBASE and CINAHL search strategy
OVID MEDLINE OVID EMBASE CINAHL through EBSCOhost
search terms for design
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized controlled trial.sh.
4. random allocation.sh.
5. double blind method.sh.
6. single blind method.sh.
7. clinical trial.pt.
8. exp clinical trial/
9. (clin$ adj25 trial$).ti,ab.
10. ((singl$ or doubl$ or trebl$ or
tripl$) adj25 (blind$ or
mask$)).ti,ab.
11. placebos.sh.
12. placebo$.ti,ab.
13. random$.ti,ab.
14. research design.sh.
15. comparative study.sh.
16. exp evaluation studies/
17. follow up studies.sh.
18. prospective studies.sh.
19. (control$ or prospectiv$ or
volunteer$).ti,ab.
search terms for design
1. randomized controlled trial.sh.
2. randomization.sh.
3. double blind procedure.sh.
4. single blind procedure.sh.
5. exp clinical trials/
6. (clin$ adj25 trial$).ti,ab.
7. ((singl$ or doubl$ or trebl$ or
tripl$) adj25
(blind$ or mask$)).ti,ab.
8. placebo.sh.
9. placebo$.ti,ab.
10. random$.ti,ab.
11. methodology.sh.
12. comparative study.sh.
13. exp evaluation studies/
14. follow up.sh.
15. prospective study.sh.
16. (control$ or prospectiv$ or
volunteer$).ti,ab.
Search terms for design
1. (MH “Clinical Trials+”)
2. (MH “Random Assignment”)
3. (MH “Double-Blind Studies”)
or
(MH “Single-Blind Studies”)
4. TX (clin$ n25 trial$)
5. TX (sing$ n25 blind$)
6. TX (sing$ n25 mask$)
7. TX (doubl$ n25 blind$)
8. TX (doubl$ n25 mask$)
9. TX (trebl$ n25 blind$)
10. TX (trebl$ n25 mask$)
11. TX (tripl$ n25 blind$)
12. TX (tripl$ n25 mask$)
13. (MH “Placebos”)
14. TX placebo$
15. TX random$
16. (MH “Study Design+”)
17. (MH “Comparative Studies”)
18. (MH “Evaluation Research”)
19. (MH “Prospective Studies+”)
20. TX (control$ or prospectiv$ or
volunteer$)
21. S1 or S2 or (…….) or S20
Search terms for Osteoarthritis
20. osteoarthriti$.ti,ab,sh.
21. osteoarthro$.ti,ab,sh.
22. gonarthriti$.ti,ab,sh.
23. gonarthro$.ti,ab,sh.
24. coxarthriti$.ti,ab,sh.
25. coxarthro$.ti,ab,sh.
26. arthros$.ti,ab.
27. arthrot$.ti,ab.
28. ((knee$ or hip$ or joint$) adj3
(pain$ or ach$ or
discomfort$)).ti,ab.
29. ((knee$ or hip$ or joint$) adj3
stiff$).ti,ab.
Search terms for Osteoarthritis
17. osteoarthriti$.ti,ab,sh.
18. osteoarthro$.ti,ab,sh.
19. gonarthriti$.ti,ab,sh.
20. gonarthro$.ti,ab,sh.
21. coxarthriti$.ti,ab,sh.
22. coxarthro$.ti,ab,sh.
23. arthros$.ti,ab.
24. arthrot$.ti,ab.
25. ((knee$ or hip$ or joint$) adj3
(pain$ or ach$ or
discomfort$)).ti,ab.
26. ((knee$ or hip$ or joint$) adj3
stiff$).ti,ab.
Search terms for Osteoarthritis
22. osteoarthriti$
23. (MH “Osteoarthritis”)
24. TX osteoarthro$
25. TX gonarthriti$
26. TX gonarthro$
27. TX coxarthriti$
28. TX coxarthro$
29. TX arthros$
30. TX arthrot$
31. TX knee$ n3 pain$
32. TX hip$ n3 pain$
33. TX joint$ n3 pain$
34. TX knee$ n3 ach$
35. TX hip$ n3 ach$
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(Continued)
36. TX joint$ n3 ach$
37. TX knee$ n3 discomfort$
38. TX hip$ n3 discomfort$
39. TX joint$ n3 discomfort$
40. TX knee$ n3 stiff$
41. TX hip$ n3 stiff$
42. TX joint$ n3 stiff$
43. S22 or S23 or S24….or S42
Search terms for TENS
30. exp electric stimulation therapy/
31. (electric$ adj (nerve or
therapy)).tw.
32. (electric$ adj (stimulation or
muscle)).tw.
33. electrostimulation.tw.
34. electroanalgesia.tw.
35. (tens or altens).tw.
36. electroacupuncture.tw.
37. neuromusc$ electric$.tw.
38. high volt.tw.
39. pulsed.tw.
40. (electric$ adj25 current).tw.
41. (electromagnetic or
electrotherap$).tw.
42. iontophoresis.tw.
43. transcutaneous nerve
stimulation.tw.
Search terms for TENS
27. exp electric stimulation therapy/
28. (electric$ adj (nerve or therapy).tw.
29. (electric$ adj (stimulation or mus-
cle)).tw.
30. electrostimulation.tw.
31. electroanalgesia.tw.
32. (tens or altens).tw.
33. electroacupuncture.tw.
34. neuromusc$ electric$.tw.
35. high volt.tw.
36. pulsed.tw.
37. electric current.sh.
38. (electric$ adj25 current).tw
39. (electromagnetic or electrotherap$).tw.
40. iontophoresis.tw.
41. transcutaneous nerve stimulation.tw.
Search terms for TENS
44. (MH “Electric Stimulation+”)
45. TX (electric$ n1 nerve)
46. TX (electric$ n1 therapy)
47. TX (electric$ n1 stimulation)
48. TX (electric$ n1 muscle)
49. TX electrostimulation
50. TX electroanalgesia
51. TX tens
52. TX altens
53. TX electroacupuncture
54. TX neuromusc$ electric$
55. TX high volt
56. TX pulsed
57. TX (electric$ n25 current)
58. TX ( (electromagnetic or elec-
trotherap$) )
59. TX iontophoresis
60. TX transcutaneous nerve stimulation
61. S44 or S45 or …. S60
Combining terms
44. or/1-19
45. or/20-29
46. or/30-40
47. and/44-46
48. animal/
49. animal/ and human/
50. 48 not 49
51. 47 not 50
Combining terms
42. or/1-16
43. or/17-26
44. or/27-37
45. and/42-44
46. animal/
47. animal/ and human/
48. 46 not 47
49. 45 not 48
Combining terms
S21 and S43 and S61
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Appendix 2. CENTRAL and PEDro search strategy
CENTRAL PEDro
Search terms for Osteoarthritis
#1. (osteoarthritis* OR osteoarthro* OR gonarthriti* OR go-
narthro*
OR coxarthriti* OR coxarthro* OR arthros* OR arthrot* OR
((knee* OR hip* OR joint*) near/3 (pain* OR ach* OR discom-
fort*))
OR ((knee* OR hip* OR joint*) near/3 stiff*)) in Clinical Trials
#2. MeSH descriptor Osteoarthritis explode all trees
Search terms for TENS
#3. MeSH descriptor Electric Stimulation Therapy explode all
trees
#4. electric* near/ (nerve or therapy) in Clinical Trials
#5. electric* near/ (stimulation or muscle) in Clinical Trials
#6. electrostimulation in Clinical Trials
#7. electroanalgesia in Clinical Trials
#8. tens or altens in Clinical Trials
#9. electroacupuncture in Clinical Trials
#10. neuromusc* electric* in Clinical Trials
#11. high volt in Clinical Trials
#12. pulsed in Clinical Trials
#13. (electric* near/25 current) in Clinical Trials
#14. (electromagnetic or electrotherap*) in Clinical Trials
#15. iontophoresis in Clinical Trials
#16. transcutaneous nerve stimulation in Clinical Trials
Combining terms
#17. (#3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10
OR
#11 OR #12 OR #13 OR #14 OR #15 OR #16)
#18. (#1 OR #2)
#19. (#17 AND #18) in Clinical Trials
1. Electro in title or abstract
2. Method: clinical trial
3. Body part: thigh or hip
4. Body part lower leg or knee
Combination 1. and 2. and 3.
Combination 1. and 2. and 4.
1. TENS in title or abstract
2. Method: clinical trial
3. Body part: thigh or hip
4. Body part lower leg or knee
Combination 1. and 2. and 3.
Combination 1. and 2. and 4.
Combine all
WH A T ’ S N E W
Last assessed as up-to-date: 1 February 2009.
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17 July 2009 New citation required and conclusions have changed Change in authors and conclusions. Updated search and
wider selection criteria, which resulted in 14 additional tri-
als; more detailed quality assessment of component trials; ex-
clusion of results from cross-over trials if treatment phases
could not be distinguished; use of end of trial estimates to
calculate SMDs; detailed exploration of sources of variation
between trials, including concealment of allocation, blind-
ing, intention-to-treat analysis, characteristics of electrostim-
ulation, and investigations of funnel plots; use of a random-
effects model.
17 July 2009 New search has been performed 14 additional trials included
1 May 2008 Amended CMSG ID C094-R
H I S T O R Y
Review first published: Issue 4, 2000
30 April 2008 Amended Converted to new review format
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Before embarking on this review, we generated a standard protocol for this and all other Cochrane Reviews performed by our group.
The protocol was approved by the Editorial Board of the Cochrane Musculoskeletal Review Group (CMSG), but, as an update, did
not result in a specific publication in the Cochrane database. We deviated from the standard protocol with respect to the selection of
main outcomes and analysis. The main outcomes specified in the protocol were pain and function, as recommended for osteoarthritis
trials. After approval of the standard protocol, the Editorial Board of CMSG reconvened several times to establish common views on
how to conduct systematic reviews, and it was decided that the main outcomes of future reviews should reflect both effectiveness and
safety. CMSG further agreed to recommend the use of a maximum of two main outcomes. Therefore, the CMSG Editorial Board and
the authors of this review agreed to specify pain intensity and the number of drop-outs or withdrawals due to adverse events as main
outcomes for this update. Function was specified as one of the secondary outcomes. The protocol specified that our main analysis would
be based on standardised mean differences (SMDs) derived from inverse-variance random-effects meta-analysis. In view of the high
degree of heterogeneity, the predominance of small trials of low methodological quality and the skewed funnel plot for pain intensity
as one of the main outcomes, we refrained from presenting the SMD of pain as primary result in main body of text and summary
of findings table, but reported results from uni-variable meta-regression analysis used to predict treatment effects in trials as large as
the largest trials included in the meta-analysis with the standard error as the explanatory variable. We acknowledge that this analysis is
exploratory, however. In addition, we used ’Risk of bias’ tables to present the methodological quality of included trials and a ’Summary
of findings’ table to present results.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Osteoarthritis, Knee [∗therapy]; Outcome Assessment (Health Care); Randomized Controlled Trials as Topic; Transcutaneous Electric
Nerve Stimulation [∗methods]
MeSH check words
Humans
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